

STIC-Bio: ch/ChemLib

From: Yaen, Christopher
Sent: Wednesday, February 12, 2003 5:14 PM
To: STIC-Biotech/ChemLib
Subject: 09924103

could you please get the following ref(s):

Eur J Immunol 1996 Dec;26(12):2924-32

Nuclear Medicine Communications, (1988) 9/10 (745-752)

INTERNATIONAL JOURNAL OF CANCER, (1982 Feb 15) 29 (2) 133-7

Christopher Yaen
Patent Examiner
US PTO
Art Unit 1642
CM1-Rm 8E18
Mail Box 8E12
703-305-3586

agf-RC261-A34

COMPLETED
Scientific and Technical
Information Center

9660853

FEB 20 RECD

PAT. & T.M. OFFICE

Searcher: _____
Phone: _____
Location: _____
Date Picked Up: _____
Date Completed: _____
Searcher Prep/Review: _____
Clerical: _____
Online time: _____

TYPE OF SEARCH:
NA Sequences: _____
AA Sequences: _____
Structures: _____
Bibliographic: _____
Litigation: _____
Full text: _____
Patent Family: _____
Other: _____

VENDOR/COST (where applic.)
STN: _____
DIALOG: _____
Questel/Orbit: _____
DRLink: _____
Lexis/Nexis: _____
Sequence Sys.: _____
WWW/Internet: _____
Other (specify): _____

STIC-Biotech/ChemLib

OR180-L-8

~~AC 261-1757~~

From: Yaen, Christopher
Sent: Wednesday, February 12, 2003 5:14 PM
To: STIC-Biotech/ChemLib
Subject: 09924103

could you please get the following ref(s):

Eur J Immunol 1996 Dec;26(12):2924-32

Nuclear Medicine Communications, (1988) 9/10 (745-752)

INTERNATIONAL JOURNAL OF CANCER, (1982 Feb 15) 29 (2) 133-7

Christopher Yaen
Patent Examiner
US PTO
Art Unit 1642
CM1-Rm 8E18
Mail Box 8E12
703-305-3586

RECEIVED
FEB 13 2003
STIC


Searcher: _____
Phone: _____
Location: _____
Date Picked Up: _____
Date Completed: _____
Searcher Prep/Review: _____
Clerical: _____
Online time: _____

TYPE OF SEARCH:

NA Sequences: _____
AA Sequences: _____
Structures: _____
Bibliographic: _____
Litigation: _____
Full text: _____
Patent Family: _____
Other: _____

VENDOR/COST (where applic.)

STN: _____
DIALOG: _____
Questel/Orbit: _____
DRLink: _____
Lexis/Nexis: _____
Sequence Sys.: _____
WWW/Internet: _____
Other (specify): _____



PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

OMIM

Bc

Search 

for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

About Entrez

Display

Abstract

Show:

20

Sort

Send to

Text

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Browser

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

☐ 1: Eur J Immunol 1996 Dec;26(12):2924-32[Related Articles, Links](#)**CD66: role in the regulation of neutrophil effector function.****Stocks SC, Ruchaud-Sparagano MH, Kerr MA, Grunert F, Haslett C, Dransfield I.**

Unit of Respiratory Medicine, University of Edinburgh Medical School, Scotland.

Neutrophils express several heavily glycosylated carcinoembryonic antigen (CEA)-related glycoproteins (CD66 antigens) which have been implicated in adhesion to E-selectin and as receptors for the lectins galectin 3 and bacterial type-1 fimbriae. The role of the CD66 antigens in neutrophil effector function was examined using non-cross-reacting and cross-reacting domain-mapped CD66 monoclonal antibody (mAb), which recognize epitopes on biliary glycoprotein (BGP; CD66a), CEA gene family member 6 (CGM6; CD66b), nonspecific cross-reacting antigen 90 (NCA90; CD66c) or CGM1 (CD66d). We show that BGP-specific mAb which recognize an AB-domain epitope strongly augment adhesion to fibrinogen by an Fc receptor- and beta2 integrin-dependent mechanism. Co-ligation of BGP with the glycoposphatidylinositol (GPI)-anchored CGM6 and NCA90 also caused increased beta2 integrin-mediated adhesion, receptor clustering and priming of formyl-Met-Leu-Phe (fMLP)-induced oxidant production by neutrophils, but only a small change in expression of L-selectin and CR3 compared to the chemotactic peptide fMLP. Ligation of CGM6 or NCA90 alone did not cause activation of the neutrophil in any of the assays used and did not cause priming of fMLP-induced oxidant production even when a secondary cross-linking reagent was used. We propose that specific cross-linking of neutrophil BGP with CGM6 and NCA90 contributes significantly to the regulation of neutrophil function during neutrophil recruitment.

PMID: 8977287 [PubMed - indexed for MEDLINE]

Display

Abstract

Show:

20

Sort

Send to

Text

[Write to the Help Desk](#)

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspal642cxy

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 BELSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 ZDB will be removed from STN
NEWS 5 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6 Records from IP.com available in CAPUS, HCAPUS, and ZCAPUS
NEWS 7 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Federal Research in Progress (FERPIP) now available
NEWS 9 New e-mail delivery for search results now available
NEWS 10 MEDLINE Reload
NEWS 11 PCTFUL has been reloaded
NEWS 12 FOREIGN no longer contains STANDARDS file segment
NEWS 13 USAN to be reloaded July 28, 2002;
NEWS 14 saved answer sets no longer valid
NEWS 15 Enhanced polymer searching in REGISTRY
NEWS 16 CANCELRIT to be removed from STN
NEWS 17 PHARMAMARKETLIER(PHARMAML) - new on STN
NEWS 18 NTIS has been reloaded and enhanced
NEWS 19 Aquatic Toxicity Information Retrieval (AQUIRE)
NEWS 20 now available on STN
NEWS 21 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 22 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 23 Sequence searching in REGISTRY enhanced
NEWS 24 JAPLO has been reloaded and enhanced
NEWS 25 Experimental properties added to the REGISTRY file
NEWS 26 CA Section Thesaurus available in CAPUS and CA
NEWS 27 CASREACT Enriched with Reactions from 1907 to 1985
NEWS 28 EVENTLINE has been reloaded
NEWS 29 BELSTEIN adds new search fields
NEWS 30 NutraSource's International (NUTRACENT) now available on STN
NEWS 31 MEDLINE SDI run of October 8, 2002
NEWS 32 DILIT has been renamed APOLIT
NEWS 33 More calculated properties added to REGISTRY
NEWS 34 TIBKAT will be removed from STN
NEWS 35 CSA files on STN
NEWS 36 PCTFUL now covers WP/PCT Applications from 1978 to date
NEWS 37 TOXCENTER enhanced with additional content
NEWS 38 Adis Clinical Trials Insight now available on STN
NEWS 39 ISMCC no longer available
NEWS 40 Indexing added to some pre-1967 records in CA/CAPUS
NEWS 41 NUTRACENT offering one free connect hour in February 2003
NEWS 42 PHARMAML offering one free connect hour in February 2003
NEWS 43 Simultaneous left and right truncation added to COMPENDEX,
ENERGY, INSPEC
NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,
CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.00b(JP),
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 14:13:41 ON 12 FEB 2003

=> file medicine, cancerlit, biosis, confict, caplus, embase, uspatfull
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'MEDLINE' ENTERED AT 14:14:19 ON 12 FEB 2003

FILE 'CANCELRIT' ENTERED AT 14:14:19 ON 12 FEB 2003

FILE 'BIOSIS' ENTERED AT 14:14:19 ON 12 FEB 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'CONFICT' ENTERED AT 14:14:19 ON 12 FEB 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'CAPLUS' ENTERED AT 14:14:19 ON 12 FEB 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 14:14:19 ON 12 FEB 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'USPATFULL' ENTERED AT 14:14:19 ON 12 FEB 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s granulocyte (a) antibody
L1 1723 GRANULOCYTE (A) ANTIBODY

=> s 11 and CML
L2 17 L1 AND CML

=> dup rem 12
PROCESSING COMPLETED FOR L2
L3 14 DUP REM L2 (3 DUPLICATES REMOVED)

=> d 1-14

L3 ANSWER 1 OF 14 USPATFULL
AN 2003:4067 USPATFULL
TI Interleukin-1 receptor antagonist-related molecules and uses thereof
IN Saris, Christian M., Newbury Park, CA, UNITED STATES
Giles, Jennifer, Newbury Park, CA, UNITED STATES

Mu, Sharon X., Thousand Oaks, CA, UNITED STATES
 Xia, Min, Newbury Park, CA, UNITED STATES
 Baese, Michael Brian, Thousand Oaks, CA, UNITED STATES
 Cavreiro, Roger, Thousand Oaks, CA, UNITED STATES
 Amgen, Inc., A Corporation of the State of Delaware (U.S. corporation)
 PI US 2003004106 AI 20030102
 PI US 2002-139833 AI 20020506 (10)
 RLI Division of Ser. No. US 2000-724583, filed on 28 Nov 2000, PENDING
 PRAI US 1999-170191P 19991210 (60)
 US 2000-188053P 20000309 (60)
 US 2000-194521P 20000404 (60)
 US 2000-195910P 20000410 (60)
 DT Utility
 FS APPLICATION
 LN CNT 5417
 INCL INCLM: 514/012.000
 INCLS: 530/350.000; 536/023.500; 435/069.100; 435/320.100; 435/325.000
 NCLM: 514/012.000
 NCLM: 514/012.000
 NCLM: 530/350.000; 536/023.500; 435/069.100; 435/320.100; 435/325.000
 IC [7]
 ICM: A61K038-17
 ICS: C07H021-04; C12P021-02; C12N005-06; C07K014-705
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 2 OF 14 USPTFULL
 L3 2002:300805 USPTFULL
 AN Allogeneic and xenogeneic transplantation
 TI Sachs, David H., Newton, MA, UNITED STATES
 IN US 2002168348 AI 20021114
 PI US 2001-874512 AI 20010605 (9)
 RLI Continuation of Ser. No. US 1998-126704, filed on 30 Jul 1998, ABANDONED
 Continuation of Ser. No. US 1995-458720, filed on 1 Jun 1995, GRANTED,
 Pat. No. US 5876708 Continuation-in-part of Ser. No. US 1994-266427,
 filed on 27 Jun 1994, GRANTED, Pat. No. US 561187 Continuation-in-part
 of Ser. No. US 1995-451210, filed on 26 May 1995, GRANTED, Pat. No. US
 6296846 Continuation of Ser. No. US 1992-838595, filed on 19 Feb 1992
 ABANDONED Continuation of Ser. No. US 1994-220371, filed on 29 Mar 1994,
 ABANDONED Continuation of Ser. No. WO 1994-243653, filed on 16 May 1994,
 GRANTED, Pat. No. US 5658564 Continuation of Ser. No. US 1993-114072,
 filed on 30 Aug 1993, GRANTED, Pat. No. US 5624823 Continuation of Ser.
 No. US 1993-150739, filed on 10 Nov 1993, UNKNOWN Continuation of Ser.
 No. US 1994-212228, filed on 14 Mar 1994, UNKNOWN Continuation of Ser.
 No. WO 1994-US1616, filed on 14 Feb 1994, UNKNOWN
 DT Utility
 FS APPLICATION
 LN CNT 3241
 INCL INCLM: 424/093.210
 INCLS: 424/093.700; 514/009.000
 NCLM: 424/093.210
 NCLM: 424/093.700; 514/009.000
 IC [7]
 ICM: A61K048-00
 ICS: A61K038-13
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 3 OF 14 USPTFULL
 L3 2002:235523 USPTFULL
 AN Specific tolerance in transplantation
 TI Sachs, David H., Newton, MA, UNITED STATES
 IN US 2002127713 AI 20020912
 PI US 2001-895713 AI 20010629 (9)
 RLI Continuation of Ser. No. US 1997-910287, filed on 13 Aug 1997, GRANTED,
 Pat. No. US 630651 Continuation of Ser. No. US 1996-759404, filed on 4
 Dec 1996, ABANDONED Continuation of Ser. No. US 1994-266427, filed on 27

Jun 1994, GRANTED, Pat. No. US 5614187 Continuation of Ser. No. US
 1993-126122, filed on 23 Sep 1993, ABANDONED Continuation of Ser. No. US
 1991-797555, filed on 22 Nov 1991, ABANDONED
 DT Utility
 FS APPLICATION
 LN CNT 1193
 INCL INCLM: 435/325.000
 INCLS: 424/093.210; 435/456.000
 NCLM: 435/325.000
 NCLM: 424/093.210; 435/456.000
 IC [7]
 ICM: A61K048-00
 ICS: C12N015-867
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 4 OF 14 USPTFULL
 L3 2002:85173 USPTFULL
 AN IL-17 receptor like molecules and uses thereof
 TI Jing, Shuguan, Thousand Oaks, CA, UNITED STATES
 IN US 2002045213 AI 20020418
 PI US 2001-809567 AI 20010315 (9)
 RLI Continuation-in-part of Ser. No. US 2000-724460, filed on 28 Nov 2000,
 PENDING
 PRAI US 2000-189816P 20000316 (60)
 DT Utility
 FS APPLICATION
 LN CNT 4685
 INCL INCLM: 435/069.100
 INCLS: 435/325.000; 530/350.000; 536/023.500; 800/008.000; 514/044.000
 NCLM: 435/069.100
 NCLM: 435/325.000; 530/350.000; 536/023.500; 800/008.000; 514/044.000
 IC [7]
 ICM: A01K067-00
 ICS: A61K048-00; C07H021-04; C12P021-02; C07K014-715
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 5 OF 14 USPTFULL
 L3 2002:66871 USPTFULL
 AN IL-17 like molecules and uses thereof
 TI Medlock, Eugene, Westlake Village, CA, UNITED STATES
 IN Yeh, Richard, Princeton, NJ, UNITED STATES
 Sillbiger, Scott M., Woodland Hills, CA, UNITED STATES
 Elliott, Gary S., Thousand Oaks, CA, UNITED STATES
 Nguyen, Hung O., Thousand Oaks, CA, UNITED STATES
 Jing, Shuguan, Thousand Oaks, CA, UNITED STATES
 PI US 2002037524 AI 20020328
 AI US 2001-886404 AI 20010621 (9)
 RLI Continuation-in-part of Ser. No. US 2001-810384, filed on 16 Mar 2001,
 PENDING
 PRAI US 2001-266159P 20010202 (60)
 DT Utility
 FS APPLICATION
 LN CNT 5737
 INCL INCLM: 435/006.000
 INCLS: 435/069.100; 435/325.000; 435/320.100; 536/023.500; 530/350.000
 NCLM: 435/006.000
 NCLM: 435/069.100; 435/325.000; 435/320.100; 536/023.500; 530/350.000
 IC [7]
 ICM: C12Q001-68
 ICS: C07H021-04; C12N005-06; C12P021-02
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ANSWER 6 OF 14 USPTFULL
 L3 2002:37315 USPTFULL
 AN

TI Immunotherapy for chronic myelocytic leukemia
IN Goldenberg, David M., Mendham, NJ, UNITED STATES
PI US 2002022031 A1 20020221
AI US 2001-924103 A1 20010808 (9)
PRAI US 2000-223698P 20000808 (60)
DT Utility
FS APPLICATION
LN CNT 1133
INCL INCLM: 424/155.100
NCL NCLM: 424/155.100
IC [7]
ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 7 OF 14 USPATFULL
AN 2002:16578 USPATFULL
TI Composition and method for treating inflammatory diseases
IN Boone, Thomas C., Newbury Park, CA, UNITED STATES
Herhenson, Susan, Newbury Park, CA, UNITED STATES
Bevilacqua, Michael P., Boulder, CO, UNITED STATES
Collins, David S., Fishers, IN, UNITED STATES
PA Amgen Inc. (U.S. corporation)
PI US 2002009454 A1 20020124
AI US 2001-784623 A1 20010215 (9)
PRAI Division of Ser. No. US 1998-131247, filed on 7 Aug 1998, PENDING
MO 1997-US2131 19970210
US 1997-55185P 19970808 (60)
DT Utility
FS APPLICATION
LN CNT 3525
INCL INCLM: 424/178.100
NCL NCLM: 424/178.100
IC [7]
ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 8 OF 14 USPATFULL
AN 2001:185089 USPATFULL
TI Specific tolerance in transplantation
IN Sachs, David H., Newton, MA, United States
PA The General Hospital Corporation, Boston, MA, United States (U.S. corporation)
PI US 6306651 B1 20011023
AI US 1997-910287 19970813 (8)
RLI Continuation of Ser. No. US 1996-759404, filed on 4 Dec 1996, now abandoned Continuation of Ser. No. US 1994-266427, filed on 27 Jun 1994, now patented, Pat. No. US 5614187 Continuation of Ser. No. US 1993-126122, filed on 23 Sep 1993, now abandoned Continuation of Ser. No. US 1991-797555, filed on 22 Nov 1991, now abandoned
DT Utility
FS GRANTED
LN CNT 1384
INCL INCLM: 435/325.000
NCL INCLM: 435/366.000; 435/372.000; 424/093.200; 424/093.210
NCLM: 435/325.000
NCLM: 424/093.200; 424/093.210; 435/366.000; 435/372.000
IC [7]
ICM: C12N015-85
ICS: A61K039-00
EXF 424/93.1; 424/93.21; 435/325; 435/366; 435/372
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 9 OF 14 USPATFULL
AN 2001:162845 USPATFULL

TI Composition and method for treating inflammatory diseases
IN Boone, Thomas C., Newbury Park, CA, United States
Herhenson, Susan, Newbury Park, CA, United States
Bevilacqua, Michael P., Boulder, CO, United States
Collins, David S., Fishers, IN, United States
PA Amgen Inc., Thousand Oaks, CA, United States (U.S. corporation)
PI US 6294170 B1 20010925
AI US 1998-131247 19980807 (9)
PRAI US 1997-55185P 19970808 (60)
DT Utility
FS GRANTED
LN CNT 3022
INCL INCLM: 424/134.100
NCL INCLM: 514/012.000; 530/324.000
NCLM: 424/134.100
NCLM: 514/012.000; 530/324.000
IC [7]
ICM: A61K038-00
ICS: A61K039-395
EXF 424/134.1; 514/12; 530/324
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 10 OF 14 USPATFULL
AN 2000:98413 USPATFULL
TI Composition and method for treating inflammatory diseases
IN Collins, David S., Lafayette, CO, United States
Bevilacqua, Michael P., Boulder, CO, United States
PA Amgen Inc., Thousand Oaks, CA, United States (U.S. corporation)
PI US 6096728 20000801
AI US 1997-798414 19970207 (8)
PRAI US 1996-11419P 19960209 (60)
US 1996-32789P 19961206 (60)
US 1997-36241P 19970123 (60)
US 1996-21443P 19960709 (60)
US 1996-36534P 19961206 (60)
US 1997-37737P 19970123 (60)
US 1997-39314P 19970207 (60)
DT Utility
FS Granted
LN CNT 2432
INCL INCLM: 514/062.000
NCL INCLM: 530/351.000
NCLM: 514/062.000
NCLM: 530/351.000
IC [7]
ICM: A61K031-70
ICS: C07K001-00
EXF 514/62; 530/351
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 11 OF 14 USPATFULL
AN 1999:27177 USPATFULL
TI Allogeneic and xenogeneic transplantation
IN Sachs, David H., Newton, MA, United States
PA The General Hospital Corporation, Boston, MA, United States (U.S. corporation)
PI US 5876708 19990302
AI US 1995-458720 19950601 (8)
RLI Continuation-in-part of Ser. No. US 1994-266427, filed on 27 Jun 1994, now patented, Pat. No. US 5614187 And Ser. No. US 1995-451210, filed on 26 May 1995, which is a continuation of Ser. No. US 1995-838595, filed on 26 May 1995, now abandoned And a continuation-in-part of Ser. No. US 1994-220371, filed on 29 Mar 1994, now abandoned Ser. No. US 1994-243653, filed on 16 May 1994, now patented, Pat. No. US 5685564 Ser. No. Ser. No. US 1993-114072, filed on 30 Aug 1993, now patented.

Pat. No. US 5624823 Ser. No. Ser. No. US 1993-150739, filed on 10 Nov 1993, now abandoned And Ser. No. US 1994-212228, filed on 14 Mar 1994, now abandoned

DT Utility
FS Granted
LN CNT 3533
INCL INCLM: 424/093.100
INCLM: 435/325.000
NCLM: 424/093.100
NCLS: 435/325.000
IC [61]
ICM: A61K038-00
ICS: C12N005-08
EXF 424/93.1: 424/93.21: 435/32.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 12 OF 14 USPATFULT
AN 97:24710 USPATFULT
TI Specific tolerance in transplantation
IN Sachs, David H.; Newton, MA, United States
PA The General Hospital Corporation, Boston, MA, United States (U.S. corporation)
The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
PI US 5614187 19970325
AI US 1994-266427 19940627 (8)
RLT Continuation of Ser. No. US 1993-126122, filed on 23 Sep 1993, now abandoned which is a continuation of Ser. No. US 1991-797555, filed on 22 Nov 1991, now abandoned

DT Utility
FS Granted
LN CNT 1304
INCL INCLM: 424/093.210
INCLM: 424/093.300; 424/577.000; 536/023.100; 536/023.500; 435/172.300
NCLM: 424/093.210
NCLS: 424/093.300; 424/577.000; 435/456.000; 536/023.100; 536/023.500
IC [61]
ICM: C12N015-00
ICS: A01N065-00; A61K035-26; C07H021-04
EXF 424/93.21: 435/172.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 13 OF 14 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B. V.
AN 92073974 EMBASE
DN 1992073974
TI Determination of anti-neutrophil cytoplasm antibodies (ANCA) specificity by immunofluorescence on chronic myelocytic leukemia cells.
AU Chevallier A.; Noel L.H.; Renier G.; Gardembas-Pain M.; Sudra J.F.; Nuberbaum P.; Hurez D.; Desavre P.
CS Laboratoire d'Immunopath., CHU, 49040 Angers Cedex, France
SO Journal of Immunological Methods, (1992) 147/1 (101-109).
CY ISSN: 0022-1759 CODEN: JIMMBC
CY Netherlands
DT Journal: Article
FS 016 Cancer
FS 025 Hematology
LA 026 Immunology, Serology and Transplantation
SL English
L3 ANSWER 14 OF 14 MEDLINE
AN 83135146 MEDLINE
DN 83135146 PubMed ID: 6962202
TI Monoclonal antibodies against human granulocytes and myeloid differentiation antigens.

AU Mannott P.; Janowska-Mieczorek A.; Turner A.R.; McGann L.; Turc J.M.
SO HUMAN IMMUNOLOGY, (1982 Dec) 5 (4) 309-23.
Journal code: 8010936. ISSN: 0198-8859.

CY United States
DT Journal: Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 198304
ED Entered STN: 19900318
Last Updated on STN: 19900318
Entered Medicine: 19830407

=> d kwic 1-14

L3 ANSWER 1 OF 14 USPATFULT
DETD . . . tumor cells. Examples of such diseases include, but are not limited to, lymphomas, bone sarcoma, chronic and acute myelogenous leukemia (CML and AML) and other leukemias, multiple myeloma, lung cancer, breast cancer, tumor metastasis, and side effects from radiation therapy. Other . . .
DETD . . . following TNF inhibitors: TNF binding proteins (soluble TNF receptor type-I and soluble TNF receptor type-II ("sTNFRs")), as defined herein), anti-TNF antibodies, granulocyte colony stimulating factor, thalidomide, BN 50730, lenidap, E 5531, tiapafant PCA 4248, nimesulide, panavir, rolipram, RP 73401, peptide T, MDL. . .

L3 ANSWER 2 OF 14 USPATFULT
DETD . . . Immunol. 9:301, is used as culture supernatant, and will be stained by mouse anti-rat IgG-specific mAb MR18.5; FITC-labelled rat-anti-mouse granulocyte antibody Gr1 is purchased from Zymed; FITC-labelled rat-anti-mouse Thy1.2 mAb will be purchased from Becton-Dickinson; FITC-labelled mouse-anti-human CD3 mAb Leu4 (Becton. . . as confirmed by FCM. These chimeras recover normal cellular immune function 2-3 months after BMT, as tested by MMR and CML. . . Four such chimeric animals (see Table 1, numbers 1-4) received kidney transplants from donors class II matched to BMT donors. . . tubulointestinal infiltrate without signs of vascular injury. Both long-term survivors (pigs #3 & 5) were recently tested for anti-donor reactivity. CML and MMR revealed specific unresponsiveness to the kidney transplant donor type cells. Pigs #8-10 received kidney transplant from outbred Yorkshire. . .

L3 ANSWER 3 OF 14 USPATFULT
DETD [0091] Anti-class I Cell-Mediated Lympholysis (CML) Assay: Spleens are removed from BMT recipients and normal mice, red cells are lysed using ACK buffer, and a single. . .
DETD . . . J. Immunol. 9:301, is used as culture supernatant, and will be stained by mouse anti-rat IgG-specific mAb MR18.5; FITC-labelled rat-anti-mouse granulocyte antibody Gr1 is purchased from Zymed; FITC-labelled rat-anti-mouse Thy1.2 mAb will be purchased from Zymed; FITC-labelled rat-anti-mouse Thy1.2 mAb will be purchased. . .

L3 ANSWER 4 OF 14 USPATFULT
DETD . . . Examples of such diseases include, but are not limited to, lymphomas, bone sarcoma, chronic and acute myelogenous leukemia (AML and CML) and other leukemias, multiple myeloma, lung, breast cancer, tumor metastasis, and side effects from radiation therapy. Other diseases involving tumor. . .
DETD . . . following TNF inhibitors: TNF binding proteins (soluble TNF receptor type-I and soluble TNF receptor type-II ("sTNFRs")), as defined herein), anti-TNF antibodies, granulocyte colony stimulating factor: thalidomide; BN 50730; lenidap; E 5531; tiapafant PCA 4248; nimesulide; panavir; rolipram; RP 73401; peptide T; MDL. . .

L3 ANSWER 5 OF 14 USPTAFULL

DETD Examples of such diseases include, but are not limited to, lymphomas, bone sarcoma, chronic and acute myelogenous leukemia (AML and CML), including myelomonocytic leukemias (M4 AML), and other leukemias, multiple myeloma, lung, breast cancer, tumor metastasis, and side effects from radiation.

DETD Following TNF inhibitors, TNF binding proteins (soluble TNF receptor type-I and soluble TNF receptor type-II ("sTNFRs")), as defined herein), anti-TNF antibodies, granulocyte colony stimulating factor; thalidomide; BN 50730; lenidap; E 5531; tiapafant PCA 4248; nimesulide; panavir; rolipram; RP 73401; peptide T; MDL are useful in the diagnosis, treatment and prevention of lymphomas including non-hodgkin's lymphoma and Hodgkin's Disease, acute myelogenous leukemias (AML and CML) including premyelocytic leukemia (M3 AML), myelomonocytic leukemia (M4 AML), erythroleukemia (M6 AML) and megakaryocytic leukemia (M7 AML); acute lymphocytic leukemia including:

AB L3 ANSWER 6 OF 14 USPTAFULL

AB Immunotherapy utilizing naked anti-granulocyte antibodies provides an effective means for treating chronic myelocytic leukemia (CML). Such antibodies can be administered alone or in combination with other therapies, such as immunoconjugates or chemotherapeutics. In either format, an effective therapy for treating CML is provided, which avoids the toxic side-effects typically associated with cancer therapy. The disclosed immunotherapy also is effective for treating:

SUMM [0001] Chronic myelocytic leukemia (CML) is a highly specific disease that is defined by strict hematologic parameters that include a pathognomonic differential leukocyte count. Usually, CML is accompanied by the presence, in bone marrow cells, of the Ph chromosome, the first chromosomal anomaly to be regularly phase when it behaves as a differentiated neoplasm and responds very well to simple, nonintensive therapy. After a variable interval, CML metamorphoses to a refractory phase that responds poorly or not at all to therapy, even when intensive. See Spiers, Semin. Oncol., 22(4):380-95 (1995). At the stage of metamorphosis a great variety of clinical and hematologic pictures occur, and CML may mimic a myeloproliferative disease, a myelodysplasia, a subacute leukemia, acute myelocytic leukemia (AML), or acute lymphocytic leukemia (ALL). The from the chronic phase to a so-called blastic crisis is incorrect. See Spiers, Semin. Oncol., 22(4):380-95 (1995). In most cases, CML is observed to undergo two or more stepwise evolutions, e.g., from chronic phase to an accelerated myeloproliferative phase to a

SUMM [0002] A variety of therapies have been used to treat CML. Traditional methods for treating leukemia, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. The use of duration of such treatments. Another therapy, allogeneic bone marrow transplants, has had the largest impact on survival among patients with CML. See Clarkson, J. Clin. Oncol., 3:115-139 (1985). Like the previous therapies, however, bone marrow transplants are poorly tolerated by patients.

SUMM [0005] There is a need, therefore, to develop immunotherapies which utilize naked antibodies to treat CML. Such therapies would cost-effectively treat patients without inducing toxic side-effects.

SUMM Objects, there is provided, in accordance with one aspect of the present invention, a method for treating chronic myelocytic leukemia (CML) in a patient, comprising administering to the patient a therapeutic composition comprising a pharmaceutically acceptable carrier and at least one naked anti-granulocyte antibody. A variety of anti-granulocyte antibodies can be used in the present invention. Examples include, but are not limited to, anti-NCA-90, anti-NCA-95, MN-2, MN-15, NP-1 and NP2. In one embodiment,

a single, naked anti-granulocyte antibody is administered to a patient while, in another, more than one anti-granulocyte antibody is administered. In still another embodiment, at least one naked anti-granulocyte antibody is administered to a patient in combination with naked antibodies directed to antigens present on a single granulocyte precursor, such.

SUMM [0008] In another embodiment of the present invention, naked anti-granulocyte antibodies are used in combination with other cancer therapies, e.g., an immunoconjugate or chemotherapy. Preferred immunoconjugates include radiolabeled antibody components and conjugates of an anti-granulocyte antibody component and an immunomodulator, such as a cytokine, stem cell growth factor, lymphotoxin or hematopoietic factor. In still another embodiment,

SUMM [0009] In yet another embodiment of the present invention, naked anti-granulocyte antibodies are administered in combination with inducing agents which either enhance or induce the expression of the targeted antigen. Such inducing surface of these cells. Accordingly, the antibodies of the present invention can be used to treat AML, as well as CML.

SUMM a patient, comprising administering to the patient a therapeutic composition comprising a pharmaceutically acceptable carrier and at least one naked anti-granulocyte antibody and an inducing agent, wherein the inducing agent induces expression of antigens which are minimally displayed on the surface of myeloblasts. As described above, the inventive method can be further combined with other naked, anti-granulocyte antibodies, antibody-toxin fusion proteins and other cancer therapies, e.g., an immunoconjugate or chemotherapy.

SUMM [0012] The present invention provides improved methods for treating myelocytic leukemia, particularly CML. The inventive methods utilize naked granulocyte-specific antibodies to destroy myeloid leukemia cells without the toxic side-effects normally associated with previous.

SUMM [0013] The anti-granulocyte antibodies used in the present invention are directed to antigens associated with various cell-types in the granulocyte lineage. Unlike in AML, malignant myeloblasts of CML patients differentiate into a variety of cell-types, including myelocytes, metamyelocytes, bands, and granulocytes. Accordingly, immunotherapy directed to one or two inventive therapy recognize immature and mature granulocytes, the present invention provides an effective method for ridding malignant cells from a CML patient's bone marrow.

SUMM [0014] A variety of anti-granulocyte antibodies can be used in the present invention. In one embodiment, the inventive methods utilize anti-NCA-90 antibodies. A preferred example of

SUMM [0020] The term "anti-granulocyte antibody" refers to an antibody which recognizes an antigen which is present on two or more cell-types of the granulocyte/myelocyte lineage.

SUMM [0057] The present invention contemplates the use of naked anti-granulocyte antibodies as the primary therapeutic composition of CML. However, in one embodiment of the invention, naked anti-granulocyte antibodies, e.g., MN-3 or MN-2, are administered to a patient in combination with one or more immunoconjugates. Such immunoconjugates can be

SUMM [0077] Therapeutic use of Anti-Granulocyte Antibodies granulocytes, the present invention provides an effective method for ridding malignant cells from a patient with myelocytic leukemia, in particular CML. As discussed above, a variety of anti-granulocyte antibodies can be used in the inventive therapy.

SUMM [0079] The present invention contemplates the use of naked anti-granulocyte antibodies as the primary therapeutic composition for treatment of CML. Such a composition can contain polyclonal anti-granulocyte antibodies or

SUMM monoclonal anti-granulocyte antibodies.

SUMM [0080] Methods for determining the binding specificity of an anti-granulocyte antibody are well-known to those of skill in the art. General methods are provided, for example, by Manson (ed.), METHODS IN . . .

SUMM [0081] In another embodiment of the present invention, naked anti-granulocyte antibodies can be used in combination with other cancer therapies, e.g., an immunoc conjugate or chemotherapy. Such combination regimens are advantageous over . . . therapy. In such multimodal regimens, the supplemental therapeutic compositions can be administered before, concurrently, or after administration of the naked anti-granulocyte antibodies.

SUMM [0082] Preferred immunoc conjugates include radiolabeled antibody components and conjugates of an anti-granulocyte antibody component and an immunomodulator. A radiolabeled immunoc conjugate may comprise an .alpha.-emitting radioisotope, a .beta.-emitting radioisotope, a .gamma.-emitting radioisotope, an Auger. . .

SUMM [0089] In another embodiment, combination therapy utilizing naked, anti-granulocyte antibodies can comprise antibody-toxin fusion proteins that comprises one or more antibody moieties. . .

SUMM [0092] Multimodal therapies of the present invention further include immunotherapy comprising two or more naked anti-granulocyte antibodies. In another embodiment, multimodal therapy comprises administration of naked anti-granulocyte antibodies supplemented with naked antibodies directed to antigens present on a single granulocyte precursor. For example, naked MN-3 antibodies can be. . .

SUMM . . . Tissue Antigens, 52:1-8 (1998). Accordingly, the antibodies of the present invention can be used to treat AML, as well as CML.

SUMM [0096] In another form of multimodal therapy, subjects receive naked anti-granulocyte antibodies and standard chemotherapy. Examples of chemotherapeutic agents include, but are not limited to, daunorubicin, cytarabine, 6-thioguanine, etoposide, mitoxantrone, diaziquone, idarubicin. . .

SUMM [0097] In general, the dosage of administered naked anti-granulocyte antibodies, immunoc conjugates, fusion proteins and additional therapeutics will vary depending upon such factors as the patient's age, weight, height, sex, general. . .

SUMM [0100] Preferably, naked anti-granulocyte antibodies are administered at low protein doses, such as 20 to 1500 milligrams protein per dose, given once, or repeatedly, parenterally. Alternatively, naked anti-granulocyte antibodies are administered in doses of 20 to 1000 milligrams protein per dose, or 20 to 500 milligrams protein per dose. . .

SUMM [0101] As described above, the present invention also contemplates therapeutic methods in which naked anti-granulocyte antibody components are supplemented with immunoc conjugate or fusion protein administration. In one variation, naked anti-granulocyte antibodies are administered with low-dose radiolabeled anti-granulocyte antibodies or fragments. As a second alternative, naked anti-granulocyte antibodies are administered with low-dose radiolabeled anti-granulocyte-cytokine immunoc conjugates. As a third alternative, naked anti-granulocyte antibodies are administered with anti-granulocyte-cytokine immunoc conjugates that are not radiolabeled. With regard to "low doses" of sup. 1311-labeled immunoc conjugates, a preferable dosage. . .

SUMM [0103] The anti-granulocyte antibodies, immunoc conjugates, and fusion proteins of the present invention can be formulated according to known methods to prepare pharmaceutically useful compositions. . .

DETD [0109] 1. Method of Treating CML using Naked Anti-NCA-90

DETD Antibody

DETD [0110] A patient with CML is treated with IFN-alpha2b for six months, but demonstrates a slow progression into the accelerated phase, with marked increase in. . .

DETD [0111] 2. Method of Treating CML using Combination Therapy

DETD [0112] A patient with CML is treated with IFN-alpha2b for six months, but demonstrates a slow progression into the accelerated phase, with marked increase in. . .

CLM What is claimed is:

1. A method for treating chronic myelocytic leukemia (CML) in a patient, comprising administering to said patient a therapeutic composition comprising a pharmaceutically acceptable carrier and at least one naked anti-granulocyte antibody.

2. The method of claim 1, wherein said anti-granulocyte antibody is an anti-NCA-90 antibody.

4. The method of claim 1, wherein said anti-granulocyte antibody is an anti-NCA-95 antibody.

5. The method of claim 1, wherein said anti-granulocyte antibody is selected from the group consisting of MN-2, MN-15, NP-1 and NP-2.

. . . a patient, comprising administering to said patient a therapeutic composition comprising a pharmaceutically acceptable carrier and at least one naked anti-granulocyte antibody, and an inducing agent, wherein said inducing agent induces expression of antibodies which are minimally displayed on the surface of. . .

7. The method of claim 1, wherein said anti-granulocyte antibody is selected from the group consisting of subhuman primate antibody, murine monoclonal antibody, chimeric antibody, humanized antibody and human antibody.

18. The method of any of claim 1, wherein said therapeutic composition comprises two or more naked anti-granulocyte antibodies.

L3 ANSWER 7 OF 14 USPTAPUL

SUMM . . . stroke, each of which may lead to neurodegeneration); lung diseases (e.g., ARDS); multiple myeloma; multiple sclerosis; myelogenous (e.g., AML and CML) and other leukemias; myopathies (e.g., muscle protein metabolism, esp. in sepsis); osteoporosis; Parkinson's disease; pain; pre-term labor; psoriasis; reperfusion injury; . . .

DETD . . . or intramuscularly for the treatment of rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, multiple myeloma, or myelogenous (e.g., AML and CML) and other leukemias. By way of example but not limitation, in a still further specific embodiment IL-1 inhibitors (e.g., preferably. . .

DETD . . . the following TNF inhibitors: TNF binding proteins (soluble TNF receptor Type I and soluble TNF receptor Type II ("sTNFRs")), anti-TNF antibodies, granulocyte colony stimulating factor; thalidomide; BN 50730; tenidap; E 5531; tlapant PCA 4246; nimesulide; panavir; rolipram; Rf 73401; peptide T; MDL. . .

DETD . . . interferon (e.g., alpha interferon, beta interferon, gamma interferon and consensus interferon) to treat multiple myeloma or myelogenous (e.g., AML and CML) and other leukemias.

L3 ANSWER 8 OF 14 USPTAPUL

DETD Anti-class I Cell-Mediated Lympholysis (CML) Assay: Spleens are removed from BMT recipients and normal mice, red cells are lysed using ACK buffer. . .

DETD . . . J. Immunol. 9:301, is used as culture supernatant, and will be

stained by mouse anti-rat IgG-specific mAb MAR18.5; FITC-labelled rat-anti-mouse granulocyte antibody Grl is purchased from Pharmingen; FITC-labelled rat-anti-mouse IgM mAb is purchased from Pharmingen; FITC-labelled rat-anti-mouse Thy1.2 mAb will be purchased.

L3 SUMM ANSWER 9 OF 14 USPATFUL.

DETD diseases (e.g., AIDS); multiple myeloma; multiple sclerosis; myelogenous (e.g., AML and CML) and other leukemias; myopathies (e.g., muscle protein metabolism, esp. in sepsis); osteoporosis; Parkinson's disease; pain; pre-term labor; psoriasis; reperfusion injury; . . . or intramuscularly for the treatment of rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, multiple myeloma, or myelogenous (e.g., AML and CML) and other leukemias. By way of example but not limitation, in a still further specific embodiment IL-1 inhibitors (e.g., preferably, . . .)

DETD . . . The following TNF inhibitors: TNF binding proteins (soluble TNF receptor Type I and soluble TNF receptor Type II ("sTNFRs")), anti-TNF antibodies, granulocyte colony stimulating factor; Thalidomide; BN 50730; tenidap; E 5531; tiapafant PCA 4248; nimesulide; panavir; rolipram; RP 73401; peptide T; MDL. . . interferon (e.g., alpha interferon, beta interferon, gamma interferon and consensus interferon) to treat multiple myeloma or myelogenous (e.g., AML and CML) and other leukemias.

L3 SUMM ANSWER 10 OF 14 USPATFUL.

DETD . . . stroke, each of which may lead to neurodegeneration; lung diseases (e.g., AIDS); multiple myeloma; multiple sclerosis; myelogenous (e.g., AML and CML) and other leukemias; myopathies (e.g., muscle protein metabolism, esp. in sepsis); osteoporosis; Parkinson's disease; pain; pre-term labor; psoriasis; reperfusion injury; . . . or intramuscularly for the treatment of rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, multiple myeloma, or myelogenous (e.g., AML and CML) and other leukemias. By way of example but not limitation, in a still further specific embodiment IL-1 inhibitors (e.g., preferably, . . .)

DETD . . . concurrent treatment) with any of one or more of the following TNF inhibitors: TNF binding proteins (soluble TNF receptors), anti-TNF antibodies, granulocyte colony stimulating factor; Thalidomide; BN 50730; tenidap; E 5531; tiapafant PCA 4248; nimesulide; panavir; rolipram; RP 73401; peptide T; MDL. . . interferon (e.g., alpha interferon, beta interferon, gamma interferon and consensus interferon) to treat multiple myeloma or myelogenous (e.g., AML and CML) and other leukemias.

L3 SUMM ANSWER 11 OF 14 USPATFUL.

DETD . . . J. Immunol. 9:301, is used as culture supernatant, and will be stained by mouse anti-rat IgG-specific mAb MAR18.5; FITC-labelled rat-anti-mouse granulocyte antibody Grl is purchased from Pharmingen; FITC-labelled rat-anti-mouse Thy1.2 mAb will be purchased from Becton-Dickinson; FITC-labelled mouse-anti-human CD3 mAb Leu4 (Becton. . .)

DETD . . . as confirmed by FCM. These chimeras recover normal cellular immune function 2-3 months after BMT, as tested by MMR and CML. . . Four such chimeric animals (see Table 1, numbers 1-4) received kidney transplants from donors class II matched to BMT donors. . . tubulointestinal infiltrate without signs of vascular injury. Both long-term survivors (pigs #3 & 5) were recently tested for anti-donor reactivity. CML and MMR revealed specific unresponsiveness to the kidney transplant donor type cells. Pigs #8-10 received kidney transplant from outbred Yorkshire. . .

L3 SUMM ANSWER 12 OF 14 USPATFUL.

DETD Anti-class I Cell-Mediated Lympholysis (CML) Assay: Spleens are removed from BMT recipients and normal mice, red cells are lysed

using ACK buffer, and a single. . .

DETD . . . J. Immunol. 9:301, is used as culture supernatant, and will be stained by mouse anti-rat IgG-specific mAb MAR18.5; FITC-labelled rat-anti-mouse granulocyte antibody Grl is purchased from Pharmingen; FITC-labelled rat-anti-mouse IgM mAb is purchased from Pharmingen; FITC-labelled rat-anti-mouse Thy1.2 mAb will be purchased.

L3 SUMM ANSWER 13 OF 14 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

AB . . . by the standard immunofluorescence method, derived from 37 patients with vasculitis were studied using formalin-acetone fixed chronic myelocytic leukemia cells (CML). All 37 sera were positive on CML cell smears. Furthermore formalin-acetone fixation selectively impaired antinuclear antibody binding without reducing ANCA staining and thus facilitated differentiation of these. . . is often difficult with the standard immunofluorescence method. Two unequivocal and mutually exclusive ANCA binding patterns were identified using the CML smears: (1) type I with diffuse granular binding confined to the polymorphonuclear (PMN) cell lineage and preferentially staining immature cells; . . .

CT Medical Descriptors: *chronic myeloid leukemia *vasculitis *wiegner granulomatosis article clinical article controlled study female human human cell immunofluorescence male priority journal *granulocyte antibody: EC, endogenous compound *myeloperoxidase: EC, endogenous compound

L3 SUMM ANSWER 14 OF 14 MEDLINE

AB . . . mice with 98% pure granulocytes from normal donors or with a whole leukocyte suspension obtained from a chronic myelogenous leukemia (CML) patient, and then fusing the mouse spleen cells with a 315-43 myeloma cell clone. Four MCA were selected and studied using ELISA, immunofluorescence, cytotoxicity assays, and FACS analysis. Antibodies 80H.1, 80H.3, and 80H.5 (from normals) and 81H.1 (from CML) detected antigens expressed on neutrophils. Antibodies 80H.1 and 80H.3 (IgG) also reacted with monocytes but not with other blood cell. . . cytotoxic and reacted strongly with most of the cells of the neutrophil maturation sequence, i.e., myeloblasts, promyelocytes, myelocytes, and mature granulocytes. Antibodies 80H.5 and 81H.1 also inhibited CFU-GM growth stimulated by leukocyte feeder layers or placental conditioned media, but did not inhibit. . .

=> d his

(FILE 'HOME' ENTERED AT 14:13:41 ON 12 FEB 2003)

FILE 'MEDLINE, CANCERLIT, BIOSIS, CONFSCT, CAPLUS, EMBASE, USPATFUL,' ENTERED AT 14:14:19 ON 12 FEB 2003

1723 S GRANULOCYTE (A) ANTIBODY

17 S L1 AND CML

14 DUP REM L2 (3 DUPLICATES REMOVED)

L3

=> s 11 and mn3

L4 22 L1 AND MN3

=> dup rem 14

PROCESSING COMPLETED FOR L4
16 DUP REM L4 (6 DUPLICATES REMOVED)

=> d 1-16

L5 ANSWER 1 OF 16 USPTFULL
AN 2002:99691 USPTFULL
TI Method and kit for imaging and treating organs and tissues
IN Goldenberg, Milton D., Mendham, NJ, UNITED STATES
PA IMMUNOMEDICS, INC. (U.S. corporation)
PI US 20020525394 A1 20020502
AI US 2001-2211 A1 20011205 (10)
R1 Division of Ser. No. US 1998-110181, filed on 6 Jul 1998, PATENTED
Division of Ser. No. US 1992-866789, filed on 7 Apr 1992, PATENTED
Continuation-in-part of Ser. No. US 1988-167077, filed on 11 Mar 1988,
PATENTED Continuation of Ser. No. US 1985-751877, filed on 5 Jul 1985,
PATENTED
DT Utility
FS APPLICATION
LN CNT 1204
INCL INCLM: 604/522.000
INCLM: 604/020.000; 424/001.490
NCL INCLM: 604/522.000
NCLM: 604/020.000; 424/001.490
IC (7)
ICM: A61M001-30
ICS: A61B005-05; A61M031-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2003 ACS DUPLICATE 1
AN 2002:21819 CAPLUS
DN 137:348485
TI Imaging of low-grade bone infection with a technetium-99m labeled
monoclonal anti-NCA-90 Fab' fragment in patients with previous joint
surgery
AU Ivancevici V.; Perka, C.; Hasart, O.; Sandrock, D.; Munz, D. L.
CS Humboldt University of Berlin, University Hospital Charite, Clinic for
European Journal of Nuclear Medicine and Molecular Imaging (2002), 29(4),
547-551
CODEN: EJNMA6
PB Springer-Verlag
DT Journal
LA English
RE CNT 12
THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT
L5 ANSWER 3 OF 16 MEDLINE
AN 2002223701 MEDLINE
DN 21911989 PubMed ID: 11914895
TI Imaging of low-grade bone infection with a technetium-99m labelled
monoclonal anti-NCA-90 Fab' fragment in patients with previous joint
surgery.
CM Erratum in: Eur J Nucl Med Mol Imaging 2002 Jun;29(6):835
AU Ivancevic V.; Perka C.; Hasart O.; Sandrock D.; Munz D.L.; Ivancevici V.
CS Clinic for Nuclear Medicine, University Hospital Charite, Humboldt
University of Berlin, Schumannstrasse 20-21, 10117 Berlin, Germany..
veimar.ivancevic@charite.de
SO Eur J Nucl Med Mol Imaging. (2002 Apr) 29 (4) 547-51.
CY Journal code: 101140988. ISSN: 1619-7070.
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals

EM 200210
Entered STN: 20020530
ED Last Updated on STN: 20030109
Entered Medicine: 20021025

L5 ANSWER 4 OF 16 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AN 2002184867 EMBASE
TI Bone marrow scintigraphy with (99m)Tc labelled monoclonal anti-NCA 90 Fab'
fragment: A feasibility study and comparison of bone marrow uptake with
(99m)Tc labelled monoclonal anti-NCA 95 antigranulocyte antibody.
AU Ivancevic V.; Huic D.; Wolter A.; Munz D.L.
CS Dr. V. Ivancevic, Clinic for Nuclear Medicine, University Hospital
Charite, Humboldt University, Schumannstr. 20-21, D-10117 Berlin, Germany..
veimar.ivancevic@charite.de
SO Nuclear Medicine Communications, (2002) 23/3 (249-255).
Ref: 25
ISSN: 0143-3636 CODEN: NMCODC
CY United Kingdom
DT Journal; Article
FS 023 Nuclear Medicine
025 Hematology
037 Drug Literature Index
LA English
SL
L5 ANSWER 5 OF 16 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. DUPLICATE
2
AN 2003:35921 BIOSIS
DN PREV200300035921
TI Scintigraphic imaging of inflammatory processes.
AU Remmen, Hub J. J. M. (1); Boerman, Otto C.; Oyen, Wim J. G.; Corstens,
Frans H. M.
CS (1) Department of Nuclear Medicine, University Medical Center Nijmegen,
6500 HB, P.O. Box 9101, Nijmegen, Netherlands: H.Remmen@negen.azn.nl
SO Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents,
(April 2002, 2002) Vol. 1, No. 1, pp. 63-75. Print.
ISSN: 1568-0142.
DT General Review
LA English
L5 ANSWER 6 OF 16 USPTFULL
AN 2001:230931 USPTFULL
TI Method and kit for imaging and treating organs and tissues
IN Goldenberg, Milton David, Short Hills, NJ, United States
PA Immunomedics, Inc., Morris Plains, NJ, United States (U.S. corporation)
PI US 6331175 B1 20011218
AI US 1998-110181 19980706 (9)
R1 Division of Ser. No. US 1992-866789, filed on 7 Apr 1992, now patented,
Pat. No. US 5776093 Continuation-in-part of Ser. No. US 1988-167077,
filed on 11 Mar 1988, now patented, Pat. No. US 5101827 Continuation of
Ser. No. US 1985-751877, filed on 5 Jul 1985, now patented, Pat. No. US
4735210
DT Utility
FS GRANTED
LN CNT 881
INCL INCLM: 604/522.000
INCLM: 604/020.000; 424/001.490
NCL INCLM: 604/522.000
NCLM: 604/020.000; 424/001.490
IC (7)
ICM: A61M025-00
ICS: 600/436; 424/1.29; 424/1.45; 424/1.49; 424/9.34; 424/9.4; 424/9.71;
530/388.8; 530/388.85; 604/20; 604/21; 604/500; 604/522; 126/898
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 16 MEDLINE
 AN 2001426446 MEDLINE
 DN 21367183 PubMed ID: 11475075
 TI Nonspecific bowel activity in imaging inflammation with Tc-99m labelled monoclonal anti-NCA-90 Fab' fragment M3.
 AU Ivancevic V; Wolter A; Munz D L
 CS Klinik für Nuklearmedizin, Universitätsklinikum Charité, Humboldt-Universität zu Berlin.. velimir.ivancevic@charite.de
 SO NUKLEARMEDIZIN, (2001 Jun) 40 (3) 71-4.
 CY Journal code: 7609387. ISSN: 0029-5566.
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200111
 ED Entered STN: 20011105
 Last Updated on STN: 20011105
 Entered Medline: 20011101

L5 ANSWER 8 OF 16 MEDLINE
 AN 1999378362 MEDLINE
 DN 99378362 PubMed ID: 10451153
 TI Use of Sulesomab, a radiolabeled antibody fragment, to detect osteomyelitis in diabetic patients with foot ulcers by leukoscintigraphy.
 AU Hatwood S J; Valdivia S; Hung G L; Quenzer R W
 CS Bay Pines Department of Veterans Affairs Medical Center, Florida 33744, USA.. hatwood.steven_j@bay-pines.va.gov
 SO CLINICAL INFECTIOUS DISEASES, (1999 Jun) 28 (6) 1200-5.
 CY Journal code: 9203213. ISSN: 1058-4838.
 DT United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199909
 ED Entered STN: 19990925
 Last Updated on STN: 19990925
 Entered Medline: 19990915

L5 ANSWER 9 OF 16 MEDLINE
 AN 199105506 MEDLINE
 DN 99105506 PubMed ID: 9890500
 TI Immunoscintigraphy of an inflammatory process in Crohn's disease with a technetium-99m-labeled fragment (M3 Fab') and with an intact monoclonal anti-granulocyte antibody (Mab BW 250/183).
 AU Kresnik E; Gallowsch H J; Mikosch P; Wolnar M; Untewegger O; Gomez I; Lind P
 CS Department of Nuclear Medicine and Endocrinology, Landeskrankenhaus Klagenfurt, Austria.. Abteiling@kh-ku.at
 SO CLINICAL NUCLEAR MEDICINE, (1999 Jan) 24 (1) 64-5.
 CY Journal code: 7611109. ISSN: 0363-9762.
 DT United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199903
 ED Entered STN: 19990326
 Last Updated on STN: 19990326
 Entered Medline: 19990316

L5 ANSWER 10 OF 16 USPATFULT
 AN 1998:78371 USPATFULT
 TI Method and kit for imaging and treating organs and tissues
 AU Goldenberg, Milton David; Short Hills, NJ, United States
 IN Immunomedics, Inc., Morris Plains, NJ, United States (U.S. corporation)

DUPLICATE 3

PI US 5776095 19980707
 AI US 1995-456914 19950601 (8)
 RLI Division of Ser. No. US 1992-866789, filed on 7 Apr 1992 which is a continuation-in-part of Ser. No. US 1988-167077, filed on 11 Mar 1988, now patented, Pat. No. US 5101827 which is a continuation of Ser. No. US 1985-751877, filed on 5 Jul 1985, now patented, Pat. No. US 4735210

DT Utility
 FS Granted
 IN.CNT 891
 INCL INCLM: 604/020.000
 INCLS: 424/001.410; 424/001.490
 NCLM: 604/020.000
 NCL NCLS: 424/001.410; 424/001.490
 IC [6]
 ICM: A61N001-30
 ICS: A61K051-00
 EXF 604/28; 604/49; 604/20; 128/898; 424/178.1; 424/1.41; 424/1.49; 424/9.34
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 11 OF 16 USPATFULT
 AN 1998:78370 USPATFULT
 TI Method and kit for imaging and treating organs and tissues
 AU Goldenberg, Milton David; Short Hills, NJ, United States
 PA Immunomedics, Inc., Morris Plains, NJ, United States (U.S. corporation)
 PI US 5776094 19980707
 AI US 1995-456629 19950601 (8)
 RLI Continuation of Ser. No. US 1992-866789, filed on 7 Apr 1992 which is a continuation-in-part of Ser. No. US 1988-167077, filed on 11 Mar 1988, now patented, Pat. No. US 5101827 which is a continuation of Ser. No. US 1985-751877, filed on 5 Jul 1985, now patented, Pat. No. US 4735210

DT Utility
 FS Granted
 LN.CNT 963
 INCL INCLM: 604/020.000
 INCLS: 600/420.000; 530/388.200; 530/391.300; 424/001.490
 NCLM: 604/020.000
 NCL NCLS: 424/001.490; 530/388.200; 530/391.300; 600/420.000
 IC [6]
 ICM: A61H001-30
 ICS: A61K035-14
 EXF 128/653.1; 128/653.2; 128/653.4; 128/654; 604/20; 604/28; 604/49; 424/1.49; 530/389.8; 530/391.3; 530/388.2; 600/410; 600/411; 600/420

L5 ANSWER 12 OF 16 USPATFULT
 AN 1998:78369 USPATFULT
 TI Method for imaging and treating organs and tissues
 AU Goldenberg, Milton David; Short Hills, NJ, United States
 PA Immunomedics, Inc., Morris Plains, NJ, United States (U.S. corporation)
 PI US 5776093 19980707
 AI US 1992-866789 19920407 (7)
 RLI Continuation-in-part of Ser. No. US 1988-167077, filed on 11 Mar 1988, now patented, Pat. No. US 5101827 which is a continuation of Ser. No. US 1985-751877, filed on 5 Jul 1985, now patented, Pat. No. US 4735210, issued on 5 Apr 1988

DT Utility
 FS Granted
 LN.CNT 875
 INCL INCLM: 604/020.000
 INCLS: 600/420.000; 530/388.200; 530/391.300; 424/001.490
 NCLM: 604/020.000
 NCL NCLS: 424/001.490; 530/388.200; 530/391.300; 600/420.000
 IC [6]
 ICM: A61N001-30
 ICS: A61K035-14
 EXF 128/653.1; 128/653.2; 128/653.4; 128/654; 436/806; 424/4; 424/7;

424/1.1; 424/1.49; 358/111; 324/307; 324/310; 604/20; 604/28; 604/49;
530/388.2; 530/389.8; 530/391.3; 600/410; 600/411; 600/420
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 13 OF 16 USPATFULL
AN 97:117409 USPATFULL
TI Method for imaging and treating organs and tissues
IN Goldenberg, Milton David, Short Hills, NJ, United States
PI Immunomedics, Inc., Morris Plains, NJ, United States (U.S. corporation)
AI US 5697902 19971216
RI US 1995-456909 19950601 (8)
Continuation of Ser. No. US 1992-866789, filed on 7 Apr 1992 which is a
continuation-in-part of Ser. No. US 1988-167077, filed on 11 Mar 1988,
now patented, Pat. No. US 5101827 which is a continuation of Ser. No. US
1985-751877, filed on 5 Jul 1985, now patented, Pat. No. US 4735210

DT Utility
FS Granted

LN CNT 913
INCL INCLM: 604/049.000

NCL INCLM: 604/021.000; 128/898.000
NCLM: 604/500.000

IC NCLS: 128/898.000; 604/021.000
[6]

EXF ICM: A61M031-00
128/898; 604/28; 604/49; 604/21

L5 ANSWER 14 OF 16 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

AN 96341152 EMBASE
DN 1996341152

TI Intruseseption secondary to Meckel's diverticulum: Detection with Tc- 99m
monoclonal antibodies to granulocytes (Leukoscan.RTM.).

AU Barron B.J.; Robins D.B.; Lamki L.M.; Daniels W.; Chopra L.; Black C.T.
Department of Radiology, University of Texas Medical School, 6431

CS Fannin, Houston, TX 77030, United States
Clinical Nuclear Medicine, (1996) 21/11 (834-837).

SO ISSN: 0363-9762 CODEN: CNMEDIK
United States

CY Journal: Article
DT

FS 007 Pediatrics and Pediatric Surgery
023 Nuclear Medicine
037 Drug Literature Index
048 Gastroenterology

LA English
SL English

L5 ANSWER 15 OF 16 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

AN 1996:144036 BIOSIS
DN PREV199698716171

TI Comparative pharmacokinetics, dosimetry, and in-vivo stability of two
formulations of 99mTc-labeled anti-granulocyte antibody

AU Fab' fragment (IMU-MN3, Leukoscan TM).
Webster, William B.; Harwood, Steven H.; Carroll, Robert G.; Morrissey,
Michele; Hakki, Sam

CS Bay Pines VA Med. Cent., Bay Pines, FL USA
Pharmacotherapy, (1996) Vol. 16, No. 1, pp. 131-132.

SO Meeting Info.: American College of Clinical Pharmacy 1996 Winter Practice
and Research Forum Monterey, California, USA February 11-14, 1996
ISSN: 0277-0008.

DT Conference
LA English

L5 ANSWER 16 OF 16 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

AN 1995:525470 BIOSIS
DN PREV1995958539770

TI The diagnostic and clinical utility of 99mTc-labeled anti-

granulocyte antibody IMU-MN3 scan (Leukoscan)
in osteomyelitis compared to MBC scans.
Quenzer, R. W. (1); Danska, Jeff; (usa), The Immunomedics Osteomyelitis
Clinical Study Group

CS (1) Univ. New Mexico, Albuquerque, NM USA
Abstracts of the Interscience Conference on Antimicrobial Agents and
Chemotherapy, (1995) Vol. 35, No. 0, pp. 77.

SO Meeting Info.: 35th Interscience Conference on Antimicrobial Agents and
Chemotherapy San Francisco, California, USA September 17-20, 1995

DT Conference
LA English

DT English

=> d ab 16

L5 ANSWER 16 OF 16 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

=> d ab 15

L5 ANSWER 15 OF 16 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

=> d 9 ab

L5 ANSWER 9 OF 16 MEDLINE

=> d his

(FILE 'HOME' ENTERED AT 14:13:41 ON 12 FEB 2003)

FILE 'MEDLINE, CANCERLIT, BIOSIS, CONSCIT, CAPLUS, EMBASE, USPATFULL'
ENTERED AT 14:14:19 ON 12 FEB 2003

1723 S GRANULOCYTE (A) ANTIBODY

L1 17 S L1 AND CML

L2 14 DUP REM L2 (3 DUPLICATES REMOVED)

L3 22 S L1 AND MN3

L4 16 DUP REM L4 (6 DUPLICATES REMOVED)

=> s 11 and administrat?
L6 293 L1 AND ADMINISTRAT?

=> dup rem 16
PROCESSING COMPLETED FOR L6
L7 282 DUP REM L6 (11 DUPLICATES REMOVED)

=> s 17 not yp=>2000

'2000' NOT A VALID FIELD CODE

'2000' NOT A VALID FIELD CODE

'2000' NOT A VALID FIELD CODE

'2000' NOT A VALID FIELD CODE

'2000' NOT A VALID FIELD CODE

'2000' NOT A VALID FIELD CODE

'2000' NOT A VALID FIELD CODE

'2000' NOT A VALID FIELD CODE

'2000' NOT A VALID FIELD CODE

'2000' NOT A VALID FIELD CODE

'2000' NOT A VALID FIELD CODE

'2000' NOT A VALID FIELD CODE

'2000' NOT A VALID FIELD CODE

'2000' NOT A VALID FIELD CODE

L10 ANSWER 1 OF 2 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
 AN 200003864 EMBASE
 TI [Immunoscintigraphy with 99mTc-labelled anti-granulocyte monovalent antibody fragments: Diagnostic features in a case of brain abscess].
 AU IMMUNOSCINTIGRAFIA CON FRAMMENTI ANTICORPAI MONOVALENTI ANTI-GRANULOCITI MARCATI CON 99^mTc: ASPETTI DIAGNOSTICI IN UN CASO DI ASCCESSO CEREBRALE.
 AU Dimonte M.; Di Pietro G.
 CS Dr. M. Dimonte, Via Alcide De Gasperi, 39, I-73100 Lecce, Italy
 SO Rivista di Neuroradiologia, (1999) 12/5 (679-684).
 Refs: 16
 ISSN: 1120-9976 CODEN: RIVNEJ
 CY Italy
 DT Journal; Article
 FS 008 Neurology and Neurosurgery
 014 Radiology
 026 Nuclear Medicine
 037 Immunology, Serology and Transplantation
 037 Drug Literature Index
 LA Italian
 SL English; Italian
 L10 ANSWER 2 OF 2 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
 AN 94276417 EMBASE
 TI Detection of soft-tissue infections and osteomyelitis using a technetium-99m-labeled anti-granulocyte monoclonal antibody fragment.
 AU Becker W.; Bahr T.; Behr T.; Repp R.; Streckenbach H.; Beck H.; Gramatzki M.; Winship M.J.; Goldenberg D.M.; Wolf F.
 CS Dept. of Nuclear Medicine, University of Erlangen-Nuremberg, Krankenhausstrasse 12, D-91054 Erlangen, Germany
 SO Journal of Nuclear Medicine, (1994) 35/9 (1436-1443).
 ISSN: 0161-5505 CODEN: JNMEAQ
 CY United States
 DT Journal; Article
 FS 023 Nuclear Medicine
 026 Immunology, Serology and Transplantation
 037 Drug Literature Index
 LA English
 SL English
 => d his
 (FILE 'HOME' ENTERED AT 14:13:41 ON 12 FEB 2003)
 FILE 'MEDLINE, CANCERLIT, BIOSIS, CONFSCI, CAPLUS, EMBASE, USPATFULT,' ENTERED AT 14:14:19 ON 12 FEB 2003
 L1 1723 S GRANULOCYTE (A) ANTIBODY
 L1 17 S L1 AND CML
 L2 14 DUP REM L2 (3 DUPLICATES REMOVED)
 L3 22 S L1 AND NM3
 L4 16 DUP REM L4 (6 DUPLICATES REMOVED)
 L5 293 S L1 AND ADMINISTRAT?
 L6 282 DUP REM L6 (11 DUPLICATES REMOVED)
 L7 282 S L7 NOT YP->2000
 L8 234 S L7 NOT PY->2000
 L9 2 S L9 AND NCA (A) 90
 L10
 => s 19 and nca
 L11 10 L9 AND NCA
 => d 1-10

L11 ANSWER 1 OF 10 MEDLINE
 AN 93235524 MEDLINE
 DN 93235524 PubMed ID: 8475680
 TI [Immunoscintigraphy for detection of inflammatory perioperative foci].
 AU Immunoscintigraphie zur Aufdeckung entzündlicher perioperativer Foci.
 AU Krotsch A; Sporn P; Auhinger G; Redl E; Bock F; Dinsl K; Neumayr A
 CS Institut für Nuklearmedizin, Krankenhausalt Rudolfstiftung, Wien.
 SO ACTA MEDICA AUSTRIACA, (1993) 20 (1-2) 45-9.
 CY Austria
 DT Journal; Article; (JOURNAL ARTICLE)
 LA German
 FS 199305
 ED Entered STN: 19930604
 Last Updated on STN: 19970203
 Entered Medline: 19930520
 L11 ANSWER 2 OF 10 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
 AN 200003864 EMBASE
 TI [Immunoscintigraphy with 99mTc-labelled anti-granulocyte monovalent antibody fragments: Diagnostic features in a case of brain abscess].
 AU IMMUNOSCINTIGRAFIA CON FRAMMENTI ANTICORPAI MONOVALENTI ANTI-GRANULOCITI MARCATI CON 99^mTc: ASPETTI DIAGNOSTICI IN UN CASO DI ASCCESSO CEREBRALE.
 AU Dimonte M.; Di Pietro G.
 CS Dr. M. Dimonte, Via Alcide De Gasperi, 39, I-73100 Lecce, Italy
 SO Rivista di Neuroradiologia, (1999) 12/5 (679-684).
 Refs: 16
 ISSN: 1120-9976 CODEN: RIVNEJ
 CY Italy
 DT Journal; Article
 FS 008 Neurology and Neurosurgery
 014 Radiology
 023 Nuclear Medicine
 026 Immunology, Serology and Transplantation
 037 Drug Literature Index
 LA Italian
 SL English; Italian
 L11 ANSWER 3 OF 10 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
 AN 1999147732 EMBASE
 TI Photopenic lesions in bone marrow scintigraphy using technetium-99m labeled anti-granulocyte antibody without known turnout.
 AU Krause Th.; Reinhardt M.; Nitzsche E.; Moser B.
 CS Th. Krause, Radiologische Klinik, Abteilung Nuklearmedizin, Hugstetter Strasse 55, D-79106 Freiburg, Germany. krause@nukl.uni-freiburg.de
 SO Nuklearmedizin, (1999) 38/3 (85-89).
 Refs: 24
 ISSN: 0029-5566 CODEN: NIMEEL
 CY Germany
 DT Journal; Article
 FS 016 Cancer
 023 Nuclear Medicine
 025 Hematology
 026 Immunology, Serology and Transplantation
 037 Drug Literature Index
 LA English
 SL English; German
 L11 ANSWER 4 OF 10 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
 AN 1998176729 EMBASE
 TI 99mTc(m)-labelled chimeric human/mouse anti-granulocyte antibody bone marrow scintigraphy: A preliminary clinical study.
 AU Higuchi T.; Inoue T.; Sarwar M.; Oriuchi N.; Karasawa M.; Naruse T.;

Yamanaka H.; Watanabe T.; Chung J.-K.; Endo K.
K. Endo, Departments of Nuclear Medicine, Gunma University School of
Medicine, 3-39-22 Showamachi, Maebashi, Gunma 371, Japan
Nuclear Medicine Communications, (1998) 19/5 (463-474).
Ref: 22
ISSN: 0143-3636 CODEN: NMCODC

CS
DN
TI
FS
CY
DT
Journal: Article
014 Radiology
016 Cancer
023 Nuclear Medicine
025 Hematology
037 Drug Literature Index
LA
SL
English

L11 ANSWER 5 OF 10 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AN 94276417 EMBASE
DN 1994276417
TI Detection of soft-tissue infections and osteomyelitis using a technetium-
99m-labeled anti-granulocyte monoclonal antibody fragment.
Becker W.; Bahr J.; Behr T.; Repp R.; Streckenbach H.; Beck H.; Gramatzki
M.; Winship M.J.; Goldenberg D.M.; Wolf F.
Dept. of Nuclear Medicine, University of Erlangen-Nuremberg,
Krankenhausstrasse 12, D-91054 Erlangen, Germany
Journal of Nuclear Medicine, (1994) 35/9 (1436-1443).
ISSN: 0161-5505 CODEN: JNMEAQ

CS
SO
CY
DT
Journal: Article
023 Nuclear Medicine
026 Immunology, Serology and Transplantation
037 Drug Literature Index
LA
SL
English

L11 ANSWER 6 OF 10 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AN 93043073 EMBASE
DN 1193043073
TI 111indium-P1ab) 2-NCA 102 monoclonal antibody: in vitro study of
a specific agent for the detection of inflammatory foci.
Collet B.; Maros S.; Moisan A.; Le Cloirec J.; Moineau M.; Aumaitre E.;
Toujas L.; Bourguet P.
Serv. Immunologie/Medecine Nucleaire, CRIC Eugene Marquis, Rue de la
Bataille Flandre-Dunkerque, 35062 Rennes Cedex, France
Nuclear Medicine and Biology, (1993) 20/2 (175-182).
ISSN: 0883-2897 CODEN: NMBIO

CS
SO
CY
DT
Journal: Article
009 Surgery
023 Nuclear Medicine
026 Immunology, Serology and Transplantation
037 Drug Literature Index
LA
SL
English

L11 ANSWER 7 OF 10 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AN 92086939 EMBASE
DN 1992086939
TI The single late 99Tcm granulocyte antibody scan in
inflammatory diseases.
Becker W.S.; Sapogino A.; Wolf F.G.
Department of Nuclear Medicine of the Friedrich-Alexander University of
Erlangen-Nuremberg, Krankenhausstrasse 12, 8520 Erlangen, Germany
Nuclear Medicine Communications, (1992) 13/3 (186-192).
ISSN: 0143-3636 CODEN: NMCODC

CY United Kingdom
DT Journal: Conference Article
FS 023 Nuclear Medicine
026 Immunology, Serology and Transplantation
037 Drug Literature Index
LA
SL
English

L11 ANSWER 8 OF 10 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AN 8900602 EMBASE
DN 198900602
TI In vivo labelling of granulocytes using 123I-tagged anti-
granulocyte antibodies.
Seybold K.
Department of Nuclear Medicine, Kantonsspital, CH-5001 Aarau, Switzerland
Nuclear Medicine Communications, (1988) 9/10 (745-752).
ISSN: 0143-3636 CODEN: NMCODC

CS
SO
CY
DT
Journal
008 Neurology and Neurosurgery
015 Chest Diseases, Thoracic Surgery and Tuberculosis
023 Nuclear Medicine
025 Hematology
026 Immunology, Serology and Transplantation
033 Orthopedic Surgery
037 Drug Literature Index
LA
SL
English

L11 ANSWER 9 OF 10 USPATFULL
AN 9744738 USPATFULL
DN 9744738
TI Detection of cardiovascular lesions
IN Goldenberg, David M., Short Hills, NJ, United States
PA Immunomedics, Inc., Morris Plains, NJ, United States (U.S. corporation)
PI US 5632968 19970527
AI US 1994-338100 19941109 (8)
RLI Continuation of Ser. No. US 1991-694977, filed on 6 May 1991, now
patented, Pat. No. US 5364612
DT Utility
FS Granted
LN.CNT 1053
INCL INCLM: 424/001.490
INGLS: 424/009.340
NCL NCLM: 424/001.490
NCLS: 424/009.340
IC [6]
ICM: A61K051-10
ICS: A61B005-055
EXF 424/1.49; 424/1.53; 424/9.34; 424/179.1; 424/180.1; 424/182.1

L11 ANSWER 10 OF 10 USPATFULL
AN 94199668 USPATFULL
TI Detection of cardiovascular lesions
IN Goldenberg, David M., Short Hills, NJ, United States
PA Immunomedics, Inc., Warren, NJ, United States (U.S. corporation)
PI US 5364612 19941115
AI US 1991-694977 19910506 (7)
DT Utility
FS Granted
LN.CNT 1163
INCL INCLM: 424/001.530
INGLS: 424/001.490; 424/009.000; 424/136.100; 424/152.100; 424/153.100;
424/154.100; 424/172.100; 424/173.100; 530/391.300
NCL NCLM: 424/001.530
NCLS: 424/001.490; 424/009.341; 424/136.100; 424/152.100; 424/153.100;

INCL INCLM: 435/226.000

INCLTS: 435/069.100; 435/325.000; 435/320.100; 536/023.200
NCLM: 435/226.000
NCLTS: 435/069.100; 435/325.000; 435/320.100; 536/023.200
IC (17)
ICM: C12N009-64
ICS: C07H021-04; C12P021-02; C12N005-06
L16 ANSWER 2 OF 18 USPATFULL
AN 2003:17897 USPATFULL
TI Nucleic acids, proteins, and antibodies
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Barash, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PI US 2003013669 A1 20030116
AI US 2001-989442 A1 20011121 (9)
RLI Continuation of Ser. No. US 2001-764863, filed on 17 Jan 2001, ABANDONED
PRAI US 2000-179065P 20000131 (60)
US 2000-180628P 20000204 (60)
US 2000-214886P 20000628 (60)
US 2000-217487P 20000711 (60)
US 2000-225758P 20000814 (60)
US 2000-220963P 20000726 (60)
US 2000-217496P 20000711 (60)
US 2000-225447P 20000814 (60)
US 2000-218290P 20000714 (60)
US 2000-225757P 20000814 (60)
US 2000-226682P 20000822 (60)
US 2000-216647P 20000707 (60)
US 2000-225267P 20000814 (60)
US 2000-216680P 20000707 (60)
US 2000-225270P 20000814 (60)
US 2000-251869P 20001208 (60)
US 2000-235834P 20000927 (60)
US 2000-234744P 20000921 (60)
US 2000-234233P 20000921 (60)
US 2000-228924P 20000830 (60)
US 2000-224518P 20000814 (60)
US 2000-236369P 20000929 (60)
US 2000-224519P 20000814 (60)
US 2000-220964P 20000726 (60)
US 2000-241809P 20001020 (60)
US 2000-249299P 20001117 (60)
US 2000-236327P 20000929 (60)
US 2000-241785P 20001020 (60)
US 2000-244617P 20001101 (60)
US 2000-225268P 20000814 (60)
US 2000-236368P 20000929 (60)
US 2000-251856P 20001208 (60)
US 2000-251868P 20001208 (60)
US 2000-229344P 20000901 (60)
US 2000-234977P 20000925 (60)
US 2000-229343P 20000901 (60)
US 2000-229345P 20000901 (60)
US 2000-229287P 20000901 (60)
US 2000-229513P 20000905 (60)
US 2000-231413P 20000908 (60)
US 2000-229505P 20000905 (60)
US 2000-236367P 20000929 (60)
US 2000-237039P 20001002 (60)
US 2000-237038P 20001002 (60)
US 2000-236370P 20000929 (60)
US 2000-236802P 20001002 (60)
US 2000-237037P 20001002 (60)
US 2000-237040P 20001002 (60)
US 2000-240960P 20001020 (60)

US 2000-239935P 20001013 (60)
US 2000-239937P 20001013 (60)
US 2000-241787P 20001020 (60)
US 2000-246474P 20001108 (60)
US 2000-246532P 20001108 (60)
US 2000-249216P 20001117 (60)
US 2000-249210P 20001117 (60)
US 2000-226681P 20000822 (60)
US 2000-225759P 20000814 (60)
US 2000-225213P 20000814 (60)
US 2000-227182P 20000822 (60)
US 2000-225214P 20000814 (60)
US 2000-235836P 20000927 (60)
US 2000-230438P 20000906 (60)
US 2000-215135P 20000630 (60)
US 2000-225266P 20000814 (60)
US 2000-249218P 20001117 (60)
US 2000-249208P 20001117 (60)
US 2000-249213P 20001117 (60)
US 2000-249212P 20001117 (60)
US 2000-249207P 20001117 (60)
US 2000-249245P 20001117 (60)
US 2000-249244P 20000927 (60)
US 2000-248217P 20001117 (60)
US 2000-249211P 20001117 (60)
US 2000-249215P 20001117 (60)
US 2000-249264P 20001117 (60)
US 2000-249214P 20001117 (60)
US 2000-249297P 20001117 (60)
US 2000-232400P 20000914 (60)
US 2000-231242P 20000908 (60)
US 2000-232081P 20000908 (60)
US 2000-232080P 20000908 (60)
US 2000-231414P 20000908 (60)
US 2000-231244P 20000908 (60)
US 2000-233063P 20000914 (60)
US 2000-232397P 20000914 (60)
US 2000-232398P 20000914 (60)
US 2000-232401P 20000914 (60)
US 2000-241808P 20001020 (60)
US 2000-241826P 20001020 (60)
US 2000-241786P 20001020 (60)
US 2000-241221P 20001108 (60)
US 2000-246475P 20000908 (60)
US 2000-231243P 20000914 (60)
US 2000-233065P 20000914 (60)
US 2000-233065P 20000914 (60)
US 2000-232398P 20000925 (60)
US 2000-246477P 20001108 (60)
US 2000-246528P 20001108 (60)
US 2000-246525P 20001108 (60)
US 2000-246476P 20001108 (60)
US 2000-246526P 20001108 (60)
US 2000-249209P 20001117 (60)
US 2000-246527P 20001108 (60)
US 2000-246523P 20001108 (60)
US 2000-246524P 20001108 (60)
US 2000-246478P 20001108 (60)
US 2000-246609P 20001108 (60)
US 2000-246613P 20001117 (60)
US 2000-249300P 20001117 (60)
US 2000-249265P 20001108 (60)
US 2000-246610P 20001108 (60)
US 2000-246611P 20001108 (60)

US 2000-230437P 20000906 (60)
US 2000-251990P 20001208 (60)
US 2000-251988P 20001205 (60)
US 2000-251030P 20001205 (60)
US 2000-251479P 20001206 (60)
US 2000-256719P 20001205 (60)
US 2000-250160P 20001201 (60)
US 2000-251989P 20001208 (60)
US 2000-250391P 20001201 (60)
US 2000-254097P 20001211 (60)
US 2000-231968P 20000912 (60)
US 2000-226279P 20000818 (60)
US 2000-186350P 20000302 (60)
US 2000-184664P 20000224 (60)
US 2000-189874P 20000316 (60)
US 2000-198123P 20000418 (60)
US 2000-227009P 20000823 (60)
US 2000-235484P 20000926 (60)
US 2000-190076P 20000317 (60)
US 2000-209467P 20000607 (60)
US 2000-205515P 20000519 (60)
US 2001-259678P 20010105 (60)
DT Utility
FS APPLICATION
LN CNT 27547
INCL INCLM: 514/012.000
INCLS: 536/023.500; 530/350.000; 435/006.000; 435/325.000; 435/069.100;
NCL NCLM: 514/012.000
NCLS: 536/023.500; 530/350.000; 435/006.000; 435/325.000; 435/069.100;
IC [7]
ICM: A61K038-17
ICS: C07K014-435; C12P021-02; C12N005-06; C12Q001-68; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L16 ANSWER 3 OF 18 USPATFULL
AN 2003:10679 USPATFULL
TI Methods and compositions relating to improved lentiviral vectors and
their applications
IN Tyono, Didier, Collonge, SWITZERLAND
PA Salmon, Patrick, Arethon, FRANCE
PI US 2003008374 A1 20030109
AI US 2001-10081 A1 20011109 (10)
PRAI US 2000-248398P 20001113 (60)
DT Utility
FS APPLICATION
LN CNT 2923
INCL INCLM: 435/235.100
INCLS: 435/456.000; 435/320.100
NCL NCLM: 435/235.100
NCLS: 435/456.000; 435/320.100
IC [7]
ICM: C12N015-867
ICS: C12N007-01
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L16 ANSWER 4 OF 18 USPATFULL
AN 2002:32926 USPATFULL
TI Polymer combinations that result in stabilized aerosols for gene
delivery to the lungs
IN Zou, Yiyu, Bronx, NY, UNITED STATES
PI Perez-Soler, Roman, New York, NY, UNITED STATES
PRAI US 2002187105 A1 20021212

AI US 2002-61444 A1 20020201 (10)
PRAI US 2001-266174P 20010201 (60)
DT Utility
FS APPLICATION
LN CNT 5666
INCL INCLM: 424/045.000
INCLS: 424/078.380; 514/002.000
NCL NCLM: 424/045.000
NCLS: 424/078.380; 514/002.000
IC [7]
ICM: A61K031-785
ICS: A61K038-15; A61L009-04; A61K031-77
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L16 ANSWER 5 OF 18 USPATFULL
AN 2002:315069 USPATFULL
TI Compositions and methods for treatment of neoplastic disease
IN Terman, David S., Pebble Beach, CA, UNITED STATES
PI US 2002177551 A1 20021128
AI US 2001-870759 A1 20010530 (9)
PRAI US 2000-208128P 20000531 (60)
DT Utility
FS APPLICATION
LN CNT 17323
INCL INCLM: 514/012.000
INCLS: 435/325.000; 530/350.000
NCL NCLM: 514/012.000
NCLS: 435/325.000; 530/350.000
IC [7]
ICM: A61K038-17
ICS: C12N005-06; C07K014-705
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L16 ANSWER 6 OF 18 USPATFULL
AN 2002:280013 USPATFULL
TI Gene differentially expressed in breast cancer, and encoded polypeptides
IN Zauderer, Maurice, Pittsford, NY, UNITED STATES
PA Evans, Elizabeth E., Rochester, NY, UNITED STATES
PI US 2002155447 A1 20021024
AI US 2001-824787 A1 20010404 (9)
PRAI US 2000-194463P 20000404 (60)
DT Utility
FS APPLICATION
LN CNT 8851
INCL INCLM: 435/006.000
INCLS: 435/007.230; 435/069.100; 435/226.000; 435/320.100; 435/325.000;
NCL NCLM: 435/006.000
NCLS: 435/007.230; 435/069.100; 435/226.000; 435/320.100; 435/325.000;
IC [7]
ICM: C12Q001-668
ICS: G01N033-574; C07H021-04; C12N009-64; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L16 ANSWER 7 OF 18 USPATFULL
AN 2002:272939 USPATFULL
TI PET DNA vector formulations for in vitro and in vivo gene delivery
IN Cristiano, Richard J., Pearland, TX, UNITED STATES
PA Yamashita, Motoyuki, Kochi City, JAPAN
PI Board of Regents, The University of Texas System (U.S. corporation)
AI US 2002151060 A1 20021017
PRAI US 2001-962922 A1 20010925 (9)
PRAI US 2000-235237P 20000925 (60)

US 2000-235635P 20000926 (60)
DT Utility
FS APPLICATION
LN.CNT 7002
INCL INCLM: 435/455.000
NCL INCLS: 514/044.000; 424/486.000
NCLM: 435/455.000
NCLS: 514/044.000; 424/486.000
IC [7]
ICM: A61K048-00
ICS: C12N015-87; A61K009-14
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 8 OF 18 USPTAFULL.
AN 2002:251760 USPTAFULL.
TI 55054, a novel human metalloprotease and uses therefor
IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES, 02139
PI US 200213713 A1 20020926
AI US 2001-963290 A1 20010925 (9)
PRAI US 2000-235055P 20000925 (60)
DT Utility
FS APPLICATION
LN.CNT 4034
INCL INCLM: 514/044.000
NCL INCLS: 435/455.000; 536/023.200
NCLM: 514/044.000
NCLS: 435/455.000; 536/023.200
IC [7]
ICM: A61K048-00
ICS: C07H021-04; C12N015-87
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 9 OF 18 USPTAFULL.
AN 2002:191201 USPTAFULL.
TI Use of monoclonal antibody 8H9
IN Cheung, Nai-Kong V., Purchase, NY, UNITED STATES
AI US 2002102284 A1 20020801
AI US 2001-982645 A1 20011018 (9)
PRAI US 2000-241344P 20001018 (60)
DT Utility
FS APPLICATION
LN.CNT 6128
INCL INCLM: 424/155.100
NCL INCLS: 424/178.100; 530/389.100; 435/326.000
NCLM: 424/155.100
NCLS: 424/178.100; 530/389.100; 435/326.000
IC [7]
ICM: A61K039-395
ICS: C07K016-46; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 10 OF 18 USPTAFULL.
AN 2002:165193 USPTAFULL.
TI Nucleic acids, proteins, and antibodies
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PI US 2002068822 A1 20020704
AI US 2001-764886 A1 20010117 (9)
PRAI US 2000-179065P 20000131 (60)
US 2000-180628P 20000204 (60)
US 2000-214866P 20000628 (60)
US 2000-217487P 20000711 (60)

US 2000-225758P 20000814 (60)
US 2000-220963P 20000726 (60)
US 2000-217496P 20000711 (60)
US 2000-225447P 20000814 (60)
US 2000-218290P 20000714 (60)
US 2000-225757P 20000814 (60)
US 2000-226868P 20000822 (60)
US 2000-216647P 20000707 (60)
US 2000-225267P 20000814 (60)
US 2000-216880P 20000707 (60)
US 2000-225270P 20000814 (60)
US 2000-2251869P 20001208 (60)
US 2000-235834P 20000927 (60)
US 2000-234274P 20000921 (60)
US 2000-234223P 20000821 (60)
US 2000-228924P 20000830 (60)
US 2000-224518P 20000814 (60)
US 2000-236369P 20000929 (60)
US 2000-224519P 20000814 (60)
US 2000-220964P 20000726 (60)
US 2000-241809P 20001020 (60)
US 2000-249299P 20001117 (60)
US 2000-236327P 20000929 (60)
US 2000-241785P 20001020 (60)
US 2000-244617P 20001101 (60)
US 2000-225268P 20000814 (60)
US 2000-236368P 20000929 (60)
US 2000-251856P 20001208 (60)
US 2000-251868P 20001208 (60)
US 2000-229344P 20000901 (60)
US 2000-234997P 20000925 (60)
US 2000-229343P 20000901 (60)
US 2000-229345P 20000901 (60)
US 2000-229287P 20000901 (60)
US 2000-229513P 20000905 (60)
US 2000-231413P 20000908 (60)
US 2000-229509P 20000905 (60)
US 2000-236367P 20000929 (60)
US 2000-237039P 20001002 (60)
US 2000-237038P 20001002 (60)
US 2000-236370P 20000929 (60)
US 2000-236802P 20001002 (60)
US 2000-237037P 20001002 (60)
US 2000-237040P 20001002 (60)
US 2000-240960P 20001020 (60)
US 2000-239355P 20001013 (60)

DT Utility
FS APPLICATION
LN.CNT 20931
INCL INCLM: 514/012.000
NCL INCLS: 435/069.100; 435/325.000; 435/320.100; 435/183.000; 536/023.100
NCLM: 514/012.000
NCLS: 435/069.100; 435/325.000; 435/320.100; 435/183.000; 536/023.100
IC [7]
ICM: A61K038-17
ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 11 OF 18 USPTAFULL.
AN 2002:165192 USPTAFULL.
TI Nucleic acids, proteins, and antibodies
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PI US 2002068821 A1 20020704

AI US 2001-764881 AI 20010117 (9)
 PRAI US 2000-179065P 20000131 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 27531
 INCL INCLM: 514/012.000
 INCLS: 536/023.100; 435/069.100; 435/183.000; 435/320.100; 435/325.000
 NCLM: 514/012.000
 NCL NCLM: 536/023.100; 435/069.100; 435/183.000; 435/320.100; 435/325.000
 IC [7]
 ICM: A61K038-17
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L16 ANSWER 12 OF 18 USPTAFULL
 AN 2002:164712 USPTAFULL
 TI Nucleic acids, proteins, and antibodies
 IN Rosen, Craig A., Laytonville, MD, UNITED STATES
 Barash, Steven C., Rockville, MD, UNITED STATES
 PI US 2002068330 AI 20020704
 AI US 2001-764893 AI 20010117 (9)
 PRAI US 2000-179065P 20000131 (60)
 US 2000-180628P 20000204 (60)
 US 2000-214886P 20000628 (60)
 US 2000-217487P 20000711 (60)
 US 2000-225758P 20000814 (60)
 US 2000-220936P 20000726 (60)
 US 2000-217496P 20000711 (60)
 US 2000-225447P 20000814 (60)
 US 2000-218290P 20000714 (60)
 US 2000-225757P 20000814 (60)
 US 2000-226868P 20000822 (60)
 US 2000-216647P 20000707 (60)
 US 2000-225267P 20000814 (60)
 US 2000-216880P 20000707 (60)
 US 2000-225270P 20000814 (60)
 US 2000-251869P 20001208 (60)
 US 2000-235834P 20000927 (60)
 US 2000-234474P 20000921 (60)
 US 2000-234423P 20000921 (60)
 US 2000-228924P 20000830 (60)
 US 2000-224518P 20000814 (60)
 US 2000-236369P 20000923 (60)
 US 2000-224519P 20000814 (60)
 US 2000-220964P 20000726 (60)
 US 2000-241809P 20001020 (60)
 US 2000-249299P 20001117 (60)
 US 2000-236327P 20000929 (60)
 US 2000-241785P 20001020 (60)
 US 2000-244617P 20001101 (60)
 US 2000-225268P 20000814 (60)
 US 2000-236368P 20000929 (60)
 US 2000-251866P 20001208 (60)
 US 2000-251868P 20001208 (60)
 US 2000-229344P 20000901 (60)
 US 2000-234937P 20000925 (60)
 US 2000-229343P 20000901 (60)
 US 2000-229345P 20000901 (60)
 US 2000-229287P 20000901 (60)
 US 2000-229513P 20000905 (60)
 US 2000-231413P 20000908 (60)
 US 2000-229509P 20000905 (60)
 US 2000-236367P 20000929 (60)
 US 2000-237039P 20001002 (60)

US 2000-237038P 20001002 (60)
 US 2000-236370P 20000929 (60)
 US 2000-236802P 20001002 (60)
 US 2000-237037P 20001002 (60)
 US 2000-237040P 20001002 (60)
 US 2000-240960P 20001020 (60)
 US 2000-239355P 20001013 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 25862
 INCL INCLM: 435/007.100
 INCLS: 536/023.100
 NCLM: 435/007.100
 NCL NCLM: 536/023.100
 IC [7]
 ICM: G01N033-53
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L16 ANSWER 13 OF 18 USPTAFULL
 AN 2002:16343 USPTAFULL
 TI Genes that regulate hematopoietic blood forming stem cells and uses thereof
 IN Lemischka, Ihor, Princeton, NJ, UNITED STATES
 PI US 2002064855 AI 20020530
 AI US 2001-789919 AI 20010221 (9)
 PRAI WO 1999-US19052 19990820
 DT Utility
 FS APPLICATION
 LN.CNT 6639
 INCL INCLM: 435/226.000
 INCLS: 435/069.100; 435/372.000; 435/320.100; 536/023.200; 435/189.000
 NCLM: 435/226.000
 NCL NCLM: 435/069.100; 435/372.000; 435/320.100; 536/023.200; 435/189.000
 IC [7]
 ICM: C12N009-02
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L16 ANSWER 14 OF 18 USPTAFULL
 AN 2002:37315 USPTAFULL
 TI Immunotherapy for chronic myelocytic leukemia
 IN Goldenberg, David M., Menham, NJ, UNITED STATES
 PI US 2002022031 AI 20020221
 AI US 2001-924103 AI 20010808 (9)
 PRAI US 2000-223698P 20000808 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1133
 INCL INCLM: 424/155.100
 NCLM: 424/155.100
 NCL NCLM: 424/155.100
 IC [7]
 ICM: A61K039-395
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L16 ANSWER 15 OF 18 USPTAFULL
 AN 2002:332463 USPTAFULL
 TI Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 (MIF-1) (Ckbeta-8/MIF-3)
 IN Li, Haodong, Gaithersburg, MD, United States
 Ruben, Steven M., Olney, MD, United States
 PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)

PI US 6495129 B1 20021217
 AI US 2000-689693 20001013 (9)
 RLI Continuation of Ser. No. US 2000-571013, filed on 15 May 2000
 Continuation-in-part of Ser. No. US 1999-334951, filed on 17 Jun 1999
 Continuation of Ser. No. US 1997-941020, filed on 30 Sep 1997, now
 abandoned Continuation-in-part of Ser. No. US 1996-722719, filed on 30
 Sep 1996, now abandoned Continuation-in-part of Ser. No. US 6001606
 Continuation-in-part of Ser. No. US 1995-468775, filed on 6 Jun 1995,
 now abandoned Continuation-in-part of Ser. No. US 1995-465682, filed on
 6 Jun 1995, now abandoned Continuation-in-part of Ser. No. US
 1995-446881, filed on 5 May 1995, now abandoned Continuation-in-part of
 Ser. No. US 468775 Continuation-in-part of Ser. No. US 465682
 Continuation-in-part of Ser. No. US 446881 Continuation of Ser. No. US
 446881, now patented, Pat. No. US 5504003 Continuation of Ser. No. US
 446881 Continuation-in-part of Ser. No. US 208339 Continuation-in-part
 of Ser. No. US 208339
 PRAI US 2000-212658P 20000619 (60)
 US 2000-211458P 20000613 (60)
 US 2000-199142P 20000424 (60)
 US 2000-189048P 20000314 (60)
 US 1999-172063P 19991223 (60)
 US 1999-164059P 19991108 (60)
 US 1999-159362P 19991016 (60)
 DT GRANTED
 FS GRANTED
 LN CNT 14198
 INCL INCLM: 424/085.100
 INCLS: 424/885.000; 514/002.000; 514/008.000; 514/012.000
 NCL INCLM: 424/085.100
 NCLS: 514/002.000; 514/008.000; 514/012.000
 IC [7]
 ICM: A61K038-19
 EXF 424/85.1; 424/885; 514/2; 514/8; 514/12
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L16 ANSWER 16 OF 18 USPATFULL
 AN 2001:231143 USPATFULL
 TI Arrays for identifying agents which mimic or inhibit the activity of
 interferons
 IN Silverman, Robert H.; Beachwood, OH, United States
 Williams, Bryan R. G., Cleveland, OH, United States
 Der, Sandy, Cleveland, OH, United States
 The Cleveland Clinic Foundation, Cleveland, OH, United States (U.S.
 corporation)
 PA US 6331396 B1 20011218
 AI US 1999-405438 19990923 (9)
 PRAI US 1998-101497P 19980923 (60)
 DT Utility
 FS GRANTED
 LN CNT 9639
 INCL INCLM: 435/006.000
 INCLS: 435/287.200; 536/023.100; 536/023.520; 536/024.300; 536/024.310.
 NCL INCLM: 435/006.000
 NCLS: 435/287.200; 536/023.100; 536/023.520; 536/024.300; 536/024.310
 IC [7]
 ICM: C120001-68
 ICS: C12M001-36; C07H021-04
 EXF 435/6; 435/287.2; 536/23.1; 536/24.31; 536/23.52
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L16 ANSWER 17 OF 18 MEDLINE
 AN 91187141 MEDLINE
 DN 91187141 Pubmed ID: 2011210

TI Distribution of carbohydrate structures in individual maturation stages of
 myeloid leukemic cells.
 AU Noworolska A; Slesak B; Harlonszinska A; Richter R
 CS Department of Pathological Anatomy, School of Medicine, Wroclaw, Poland.
 SO NEOPLASMA. (1991) 38 (1) 57-62.
 CY Journal code: 0377266. ISSN: 0028-2685.
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199105
 ED Entered STN: 19910526
 Last Updated on STN: 19960719
 Entered Medline: 19910503
 L16 ANSWER 18 OF 18 MEDLINE
 AN 82141196 MEDLINE
 DN 82141196 Pubmed ID: 6949877
 TI Clinical evaluation of NCA in patients with chronic myelocytic
 leukemia.
 AU Wahren B; Gahrton G; Ruden U; Hammarstrom S
 SO INTERNATIONAL JOURNAL OF CANCER. (1982 Feb 15) 29 (2) 133-7.
 CY Journal code: 0042124. ISSN: 0020-7136.
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 198205
 ED Entered STN: 19900317
 Last Updated on STN: 19900317
 Entered Medline: 19820512
 = > d 17 18 ibib ab
 L16 ANSWER 17 OF 18 MEDLINE
 AN 91187141 MEDLINE
 DN 91187141 Pubmed ID: 2011210
 TI Distribution of carbohydrate structures in individual
 maturation stages of myeloid leukemic cells.
 AU Noworolska A; Slesak B; Harlonszinska A; Richter R
 CS Department of Pathological Anatomy, School of Medicine,
 Wroclaw, Poland.
 SO NEOPLASMA. (1991) 38 (1) 57-62.
 CY Journal code: 0377266. ISSN: 0028-2685.
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199105
 ED Entered STN: 19910526
 Last Updated on STN: 19960719
 Entered Medline: 19910503
 AB The distribution of peanut agglutinin (PNA) receptors, nonspecific
 cross-reacting antigen (NCA) molecule and 3-fucosyl-N-
 acetylglucosamine (FAL) in myeloid leukemic cells isolated by density
 gradient centrifugation was compared using immunofluorescence test (IF).
 Patients with acute myelocytic leukemias (AML) type M2 and M5 showed low
 percentage of NCA+ and PNA+ cells. In chronic and acute phase of
 chronic myelocytic leukemias (CML) the number of NCA
 containing cells increased and the amount of PNA-binding cells decreased
 as more mature granulocytic fractions were isolated on Ficoll-Uroplone
 density gradient. In patients with myeloblastic crisis of CML (CML-BC)
 the number of cells expressing FAL structure did not
 change in relation to maturation stage of myeloid cells. Our results

⇒ S 114 and humaniz?

L19 ANSWER 2 OF 24 USPATFULL
AN 2003:24162 USPATFULL
TI Gene therapy of diseases associated with the immune system, using a cell-specific active compound which is regulated by the cell cycle
IN Sedlack, Hans-Harald, Marburg, GERMANY, FEDERAL REPUBLIC OF
Muller, Rolf, Marburg, GERMANY, FEDERAL REPUBLIC OF

PI US 2003018005 A1 20030123
 AI US 2002-112953 A1 20020402 (10)
 RLI Continuation of Ser. No. US 1997-793109, filed on 25 Apr 1997, GRANTED,
 Pat. No. US 6384202
 PRAI GB 1994-17366 19940826
 GB 1995-6466 19950329
 DE 1995-19524720 19950712
 DT Utility
 FS APPLICATION
 LN CNT 3163
 INCL INCLM: 514/044.000
 INCLM: 536/023.200; 536/023.500
 NCL NCLM: 514/044.000
 NCLM: 536/023.200; 536/023.500
 IC [7]
 ICM: A61K048-00
 ICS: C07H021-04
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 3 OF 24 USPATFULL
 AN 2002:315069 USPATFULL
 TI Compositions and methods for treatment of neoplastic disease
 IN Terman, David S., Pebble Beach, CA, UNITED STATES
 PI US 2002177551 A1 20021128
 AI US 2001-870759 A1 20010530 (9)
 PRAI US 2000-208128P 20000531 (60)
 DT Utility
 FS APPLICATION
 LN CNT 1733
 INCL INCLM: 514/012.000
 INCLM: 435/325.000; 530/350.000
 NCL NCLM: 514/012.000
 NCLM: 435/325.000; 530/350.000
 IC [7]
 ICM: A61K038-17
 ICS: C12N005-06; C07K014-705
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 4 OF 24 USPATFULL
 AN 2002:301110 USPATFULL
 TI Hematopoietic growth factor inducible neurokinin-1 gene
 IN Rameshwar, Praneela, Maplewood, NJ, UNITED STATES
 PA University of Medicine & Dentistry of New Jersey (2)
 PI US 2002168653 A1 20021114
 AI US 2001-39272 A1 20011020 (10)
 PRAI US 2000-241881P 20001020 (60)
 DT Utility
 FS APPLICATION
 LN CNT 3139
 INCL INCLM: 435/006.000
 INCLM: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
 NCL NCLM: 435/006.000
 NCLM: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
 IC [7]
 ICM: C120001-68
 ICS: C07H021-04; C12P021-02; C12N005-06; C07K014-705
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 5 OF 24 USPATFULL
 AN 2002:213436 USPATFULL
 TI Restore cancer-suppressing functions to neoplastic cells through DNA
 hypomethylation
 IN Rubinfeld, Joseph, Danville, CA, UNITED STATES
 Chang, Lucy, San Mateo, CA, UNITED STATES
 DiMartino, Jorge, San Carlos, CA, UNITED STATES

PI US 2002114809 A1 20020822
 AI US 2001-790483 A1 20010221 (9)
 DT Utility
 FS APPLICATION
 LN CNT 1466
 INCL INCLM: 424/155.100
 INCLM: 424/277.100; 424/649.000; 514/254.070; 514/269.000; 514/283.000;
 514/171.000; 514/183.000; 514/027.000; 514/034.000; 514/049.000
 NCL NCLM: 424/155.100
 NCLM: 424/277.100; 424/649.000; 514/254.070; 514/269.000; 514/283.000;
 514/171.000; 514/183.000; 514/027.000; 514/034.000; 514/049.000
 IC [7]
 ICM: A61K039-00
 ICS: A61K039-395; A61K031-57; A61K031-495
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 6 OF 24 USPATFULL
 AN 2002:191201 USPATFULL
 TI Uses of monoclonal antibody 8H9
 IN Cheung, Nai-Kong V., Purchase, NY, UNITED STATES
 PI US 2002102264 A1 20020801
 AI US 2001-982645 A1 20011018 (9)
 PRAI US 2000-241344P 20001018 (60)
 DT Utility
 FS APPLICATION
 LN CNT 6128
 INCL INCLM: 424/155.100
 INCLM: 424/178.100; 530/389.100; 435/326.000
 NCL NCLM: 424/155.100
 NCLM: 424/178.100; 530/389.100; 435/326.000
 IC [7]
 ICM: A61K039-395
 ICS: C07K016-46; C12N005-06
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 7 OF 24 USPATFULL
 AN 2002:126868 USPATFULL
 TI 18221, a novel dual specificity phosphatase and uses thereof
 IN Meyers, Rachel A., Newton, MA, UNITED STATES
 PI US 2002065406 A1 20020530
 AI US 2001-815419 A1 20010322 (9)
 PRAI US 2000-191858P 20000324 (60)
 DT Utility
 FS APPLICATION
 LN CNT 5161
 INCL INCLM: 536/023.100
 INCLM: 435/006.000; 435/196.000
 NCL NCLM: 536/023.100
 NCLM: 435/006.000; 435/196.000
 IC [7]
 ICM: C07H021-02
 ICS: C07H021-04; C120001-68; C12N009-16
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 8 OF 24 USPATFULL
 AN 2002:781994 USPATFULL
 TI Immunotherapy of malignant and autoimmune disorders in domestic animals
 using naked antibodies, immunocjugates and fusion proteins
 IN Goldenberg, David W., Mendham, NJ, UNITED STATES
 PI US 2002041847 A1 20020411
 AI US 2001-921290 A1 20010803 (9)
 RLI Continuation-in-part of Ser. No. US 1998-38995, filed on 12 Mar 1998,
 GRANTED, Pat. No. US 6134982 Continuation-in-part of Ser. No. US
 1999-307816, filed on 10 May 1999, GRANTED, Pat. No. US 6306393
 DT Utility

IC NCLTS: 435/233.000; 536/023.500
 [7]
 ICM: C07H021-04
 ICS: C12N009-90
 EXP 435/233; 435/252.3; 435/325; 536/23.2; 536/23.5
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 14 OF 24 USPATFULL
 AN 2002:174981 USPATFULL
 TI 18232, a novel dual specificity phosphatase and uses thereof
 IN Meyers, Rachel A., Newton, MA, United States
 PA Weich, Nadine, Brookline, MA, United States
 PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
 PI US 6420155 B1 20020716
 AI US 2000-704139 20001101 (9)
 PRAI US 2000-185772P 20000229 (60)
 DT Utility
 FS GRANTED
 INCL INCLM: 435/196.000
 INCLTS: 435/252.300; 435/320.100; 435/325.000; 536/023.200; 536/023.100; 536/024.100
 NCL NCLM: 435/196.000
 NCLTS: 435/252.300; 435/320.100; 435/325.000; 536/023.100; 536/023.200; 536/024.100
 IC [7]
 ICM: C12N009-16
 ICS: C12N001-20; C12N005-00; C07H021-02; C07H021-04
 EXP 435/196; 435/252.3; 435/320.1; 435/325; 536/23.2; 536/23.1; 536/24.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 15 OF 24 USPATFULL
 AN 2002:102621 USPATFULL
 TI Cell-specific active compounds regulated by the cell cycle
 IN Sedlacker, Hans-Harald, Marburg, GERMANY, FEDERAL REPUBLIC OF
 PA Muller, Rolf, Marburg, GERMANY, FEDERAL REPUBLIC OF
 PA Hoechst Aktiengesellschaft, Frankfurt am Main, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
 PI US 6384202 B1 20020507
 WO 9606941 19960307
 AI US 1997-793109 19970425 (8)
 WO 1995-EP3371 19950825
 PRAI GB 1994-17366 19970425 PCT 371 date
 GB 1995-6466 19950329
 DE 1995-19524720 19950712
 DT Utility
 FS GRANTED
 INCL INCLM: 536/023.100
 INCLTS: 424/093.100; 424/093.200; 424/093.600; 435/320.100; 536/023.500; 536/024.100
 NCL NCLM: 536/023.100
 NCLTS: 424/093.100; 424/093.200; 424/093.600; 435/320.100; 536/023.500; 536/024.100
 IC [7]
 ICM: A01N063-00
 ICS: A61K048-00; C07H021-02; C12N015-63
 EXP 536/23.5; 536/24.1; 536/23.1; 514/44; 435/320.1; 424/93.1; 424/93.2; 424/93.6
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 16 OF 24 USPATFULL
 AN 1999:170208 USPATFULL

TI Therapeutic uses of the hypervariable region of monoclonal
 IN antibody M195 and constructs thereof
 PA Scheinberg, David A., New York, NY, United States
 PA Sloan-Kettering Institute for Cancer Research, New York, NY, United States (U.S. corporation)
 PI US 6007814 19991228
 AI US 1992-861967 19920615 (7)
 RLI Continuation-in-part of Ser. No. US 450918
 DT Utility
 FS GRANTED
 INCL INCLM: 424/130.100
 INCLTS: 424/133.100; 424/152.100; 424/153.100; 424/155.100; 424/173.100; 424/178.100; 424/183.100; 530/387.300; 530/387.700; 530/388.200; 530/388.700; 530/388.800; 530/389.600; 530/389.700; 530/391.300; 530/391.700
 NCL NCLM: 424/130.100
 NCLTS: 424/133.100; 424/152.100; 424/153.100; 424/155.100; 424/173.100; 424/178.100; 424/183.100; 530/387.300; 530/387.700; 530/388.200; 530/388.600; 530/388.700; 530/388.800; 530/389.600; 530/389.700; 530/391.300; 530/391.700
 IC [6]
 ICM: C07K016-28
 ICS: C07K016-46; A61K039-395
 EXP 530/387.3; 530/387.7; 530/387.73; 530/387.75; 530/388; 530/8; 530/391.7; 530/391.3; 530/388.2; 530/388.7; 530/389.6; 530/389.7; 435/240.27; 435/72.2; 435/70.21; 424/134.1; 424/138.1; 424/153.1-156.1; 424/130.1; 424/133.1; 424/152.1; 424/173.1; 424/178.1; 424/183.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 17 OF 24 USPATFULL
 AN 1999:27752 USPATFULL
 TI Process for preparing conjugates of methyltrithio antitumor agents
 IN Hamann, Philip Ross, Garnerville, NY, United States
 IN Hamann, Lois, N. Tarrytown, NY, United States
 PA Hollander, Irwin, Monsey, NY, United States
 PA Holcomb, Ryan, Glen Rock, NJ, United States
 PA Hallett, William, New City, NY, United States
 PA Toul, Hwei-Ru, New City, NY, United States
 PA Weiss, Martin J., Ft. Lee, NJ, United States
 PA American Cyanamid Company, Madison, NJ, United States (U.S. corporation)
 PI US 5877296 19990302
 AI US 1995-452164 19950526 (8)
 RLI Division of Ser. No. US 1994-253877, filed on 3 Jun 1994, now patented, Pat. No. US 5773001
 DT Utility
 FS GRANTED
 INCL INCLM: 530/391.700
 INCLTS: 514/025.000; 514/026.000; 514/053.000; 514/168.000; 530/391.100; 530/391.900
 NCL NCLM: 530/391.700
 NCLTS: 530/391.100; 530/391.900
 IC [6]
 ICM: C07K016-00
 ICS: A01N043-04; C12P019-44
 EXP 530/391.1; 530/391.7; 530/391.9; 514/25; 514/26; 514/53; 514/168
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 18 OF 24 USPATFULL
 AN 1998:75158 USPATFULL
 TI Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
 IN Hamann, Philip Ross, Garnerville, NY, United States
 IN Hamann, Lois, N. Tarrytown, NY, United States

NCL NCLM: 435/007.240
 NCLS: 435/002.000; 435/030.000; 435/343.000; 435/372.000; 530/388.700
 IC [6]
 ICM: C07K016-28
 EXF 435/2; 435/7.24; 435/30; 435/240.2; 435/240.27; 530/388.7
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 23 OF 24 USPATFULL
 AN 97:44908 USPATFULL
 TI WT1 monoclonal antibodies and methods of use therefor
 IN Herlyn, Menhard, Wynneood, PA, United States
 Morris, Jennifer, Brookfield, WI, United States
 Rauscher, III, Frank J., Cranbury, NJ, United States
 Rodock, Ulrich, Philadelphia, PA, United States
 PA The Wistar Institute of Anatomy and Biology, Philadelphia, PA, United States (U.S. corporation)
 PI US 5633142 19970527
 AI US 1995-456907 19950601 (8)
 RLI Continuation-in-part of Ser. No. US 1994-234783, filed on 28 Apr 1994
 DT Utility
 FS Granted
 LN.CNT 1214
 INCL INCLM: 435/007.230
 INCLS: 435/007.100; 435/007.200; 435/007.210; 530/387.100; 530/387.700;
 NCL NCLM: 435/007.230
 NCLS: 435/007.100; 435/007.200; 435/007.210; 530/387.100; 530/387.700;
 IC [6]
 ICM: G01N033-547
 EXF 435/7.23; 435/7.1; 435/7.2; 435/7.21; 530/387.1; 530/387.7; 530/388.1;
 530/388.8; 530/809
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 24 OF 24 USPATFULL
 AN 97:33630 USPATFULL
 TI WT1 monoclonal antibodies
 IN Herlyn, Menhard, Wynneood, PA, United States
 Morris, Jennifer, Wilmington, DE, United States
 Rauscher, III, Frank J., Cranbury, NJ, United States
 Rodock, Ulrich, Philadelphia, PA, United States
 PA The Wistar Institute of Anatomy & Biology, Philadelphia, PA, United States (U.S. corporation)
 PI US 5622835 19970422
 AI US 1994-234783 19940428 (8)
 DT Utility
 FS Granted
 LN.CNT 1265
 INCL INCLM: 435/328.000
 INCLS: 530/387.300; 530/387.900; 530/388.100; 530/388.800; 530/388.850;
 NCL NCLM: 435/328.000
 NCLS: 435/070.210; 435/172.200; 435/331.000; 435/344.000; 435/344.100
 IC [6]
 ICM: C12N005-12
 EXF 435/240.27; 435/172.2; 435/70.21; 435/7.23; 530/387.3; 530/387.9;
 530/388.1; 530/388.85; 530/388.8
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

(FILE 'HOME' ENTERED AT 14:13:41 ON 12 FEB 2003)
 FILE 'MEDLINE, CANCERLIT, BIOSIS, CONFSCI, CAPLUS, EMBASE, USPATFULL'
 ENTERED AT 14:14:19 ON 12 FEB 2003
 1723 S GRANULOCYTE (A) ANTIBODY
 L1 17 S L1 AND CML
 L2 14 DUP REM L2 (3 DUPLICATES REMOVED)
 L3 22 S L1 AND MN3
 L4 16 DUP REM L4 (6 DUPLICATES REMOVED)
 L5 293 S L1 AND ADMINSTRAT?
 L6 282 DUP REM L6 (11 DUPLICATES REMOVED)
 L7 282 S L7 NOT YP->2000
 L8 234 S L7 NOT PY->2000
 L9 2 S L9 AND NCA (A) 90
 L10 10 S L9 AND NCA
 L11 32001 S CML
 L12 3824 S L12 AND GRANULOCYTE
 L13 831 S L13 AND ANTIBOD?
 L14 23 S L14 AND NCA?
 L15 18 DUP REM L15 (5 DUPLICATES REMOVED)
 L16 204 S L14 AND HUMANIT?
 L17 24 S L17 AND CD13
 L18 24 DUP REM L18 (0 DUPLICATES REMOVED)
 L19
 => S 114 and treat?
 L20 537 L14 AND TREAT?
 => S 120 and mn3
 L21 0 L20 AND MN3
 => S 120 and mn2
 L22 1 L20 AND MN2
 => d 1 ab
 L22 ANSWER 1 OF 1 USPATFULL
 AB The invention provides isolated nucleic acids molecules, designated 56294 and 56229 nucleic acid molecules, which encode novel metalloprotease family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 56294 or 56229nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 56294 or 56229 gene has been introduced or disrupted. The invention still further provides isolated 56294 or 56229 proteins, fusion proteins, antigenic peptides and anti-56294, anti-56229 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

=> d 1 hb1b
 L22 ANSWER 1 OF 1 USPATFULL
 ACCESSION NUMBER: 2003,23732 USPATFULL
 TITLE: 56294 and 56229, novel human metalloproteases and uses thereof
 INVENTOR(S): Bandaru, Rajasekhar, Watertown, MA, UNITED STATES

NUMBER	KIND	DATE
US 2003017572	A1	20030123
US 2001-961656	A1	20010924 (9)

PATENT INFORMATION:
 APPLICATION INFO.:
 NUMBER DATE

PRIORITY INFORMATION: US 2000-235035P 20000925 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 6 Drawing Page(s)
NUMBER OF DRAWINGS: 5895
LINE COUNT: 5895
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 14:13:41 ON 12 FEB 2003)

FILE 'MEDLINE, CANCERLIT, BIOSIS, CONFSCI, CAPLUS, EMBASE, USPATFULT'
ENTERED AT 14:14:19 ON 12 FEB 2003

L1 1723 S GRANULOCYTE (A) ANTIBODY
L2 17 S L1 AND CML
L3 14 DUP REM L2 (3 DUPLICATES REMOVED)
L4 22 S L1 AND MN3
L5 16 DUP REM L4 (6 DUPLICATES REMOVED)
L6 293 S L1 AND ADMINISTRAT?
L7 282 DUP REM L6 (11 DUPLICATES REMOVED)
L8 282 S L7 NOT YP=>2000
L9 234 S L7 NOT PY=>2000
L10 2 S L9 AND NCA (A) 90
L11 10 S L9 AND NCA
L12 32001 S CML
L13 3824 S L12 AND GRANULOCYTE
L14 831 S L12 AND ANTIBOD?
L15 23 S L14 AND NCA?
L16 18 DUP REM L15 (5 DUPLICATES REMOVED)
L17 204 S L14 AND HUMANIZ?
L18 24 S L17 AND CD33
L19 24 DUP REM L18 (0 DUPLICATES REMOVED)
L20 537 S L14 AND TREAT?
L21 0 S L20 AND MN3
L22 1 S L20 AND MN2

=> s 120 and cea
L23 13 L20 AND CEA

=> dup rem 123
PROCESSING COMPLETED FOR L23
L24 13 DUP REM L23 (0 DUPLICATES REMOVED)

=> d 1-13

L24 ANSWER 1 OF 13 USPATFULT
AN 2003:23733 USPATFULT
TI Polymerase kappa compositions and methods thereof
IN Friedberg, Errol C., Dallas, TX, UNITED STATES
Geilach, Valerie, Branford, CT, UNITED STATES
Feaver, William J., Branford, CT, UNITED STATES
BA Board of Regents, The University of Texas system (U.S. corporation)
PI US 2003:017573 AI 2003:0123
AI US 2001-971101 AI 2003:0123 (9)
PRAI US 2000-238289P 2000:1004 (60)
DT Utility
FS APPLICATION
LN.CNT 7042
INCL INCLM: 435/226.000
INCLS: 435/069.100; 435/325.000; 435/320.100; 536/023.200

NCL NCLM: 435/226.000
NCLS: 435/069.100; 435/325.000; 435/320.100; 536/023.200
IC [7]
ICM: C12N009-64
ICS: C07H021-04; C12P021-02; C12N005-06

L24 ANSWER 2 OF 13 USPATFULT
AN 2002:191201 USPATFULT
TI Uses of monoclonal antibody 8H9
IN Cheung, Nai-Kong V., Purchase, NY, UNITED STATES
PI US 2002:102264 AI 2002:0801
AI US 2001-982645 AI 2001:1018 (9)
PRAI US 2000-241344P 2000:1018 (60)
DT Utility
FS APPLICATION

LN.CNT 6128
INCL INCLM: 424/155.100
NCL INCLM: 424/178.100; 530/389.100; 435/326.000
NCLS: 424/178.100; 530/389.100; 435/326.000
IC [7]
ICM: A61K039-395
ICS: C07K016-46; C12N005-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 3 OF 13 USPATFULT
AN 2002:37315 USPATFULT
TI Immunotherapy for chronic myelocytic leukemia
IN Goldensberg, David M., Mendham, NJ, UNITED STATES
Hansen, Hans J., Sidell, IA, UNITED STATES
PI US 2002:022031 AI 2002:0221
AI US 2001-924103 AI 2001:0808 (9)
PRAI US 2000-223698P 2000:0808 (60)
DT Utility
FS APPLICATION

LN.CNT 1133
INCL INCLM: 424/155.100
NCL INCLM: 424/155.100
IC [7]
ICM: A61K039-395

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 4 OF 13 USPATFULT
AN 2002:22535 USPATFULT
TI PROCESS FOR PRODUCING ARSENIC TRIOXIDE FORMULATIONS AND METHODS FOR
IN TREATING CANCER USING ARSENIC TRIOXIDE OR MELARSOPROL
WARRELL, RAYMOND P., JR., WESTFIELD, NJ, UNITED STATES
PANDOLFI, PIER PAOLO, NEW YORK, NY, UNITED STATES
GABRILOVE, JANICE L., NEW YORK, NY, UNITED STATES
PI US 2002:013371 AI 2002:0131
AI US 1998-189965 AI 1998:1110 (9)
PRAI US 1997-64655P 1997:1110 (60)
DT Utility
FS APPLICATION
LN.CNT 1391
INCL INCLM: 514/623.000
NCL INCLM: 514/623.000
IC [7]
ICM: A61K031-47
ICS: A61K031-165

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 5 OF 13 USPATFULT
AN 2002:332463 USPATFULT
TI Methods of inhibiting hematopoietic stem cells using human myeloid

IN progenitor inhibitory factor-1 (MIF-1) (Ckbeta-8/MIP-3)
 LA, Hadong, Galtersburg, MD, United States
 PA Ruben, Steven M., Olney, MD, United States
 PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)
 PI US 6495129 B1 20021217
 RLI US 2000-689693 B1 20021013 (9)
 Continuation of Ser. No. US 2000-571013, filed on 15 May 2000
 Continuation-in-part of Ser. No. US 1999-334951, filed on 17 Jun 1999
 Continuation of Ser. No. US 1997-941020, filed on 30 Sep 1997, now
 abandoned Continuation-in-part of Ser. No. US 1996-722723, filed on 30
 Sep 1996, now abandoned Continuation-in-part of Ser. No. US 1996-722719,
 filed on 30 Sep 1996, now patented, Pat. No. US 6001606
 Continuation-in-part of Ser. No. US 1995-468775, filed on 6 Jun 1995,
 now abandoned Continuation-in-part of Ser. No. US 1995-465682, filed on
 6 Jun 1995, now abandoned Continuation-in-part of Ser. No. US 1995-465682, filed on
 1995-46881, filed on 5 May 1995, now abandoned Continuation-in-part of
 Ser. No. US 468775 Continuation-in-part of Ser. No. US 465682
 Continuation-in-part of Ser. No. US 446881 Continuation of Ser. No. US
 446881 Continuation-in-part of Ser. No. US 1994-208339, filed on 8 Mar
 1994, now patented, Pat. No. US 5504003 Continuation of Ser. No. US
 446881 Continuation-in-part of Ser. No. US 208339 Continuation-in-part
 of Ser. No. US 208339
 PRAI US 2000-212658P 20000619 (60)
 US 2000-211458P 20000613 (60)
 US 2000-199142P 20000424 (60)
 US 2000-189048P 20000314 (60)
 US 1999-172063P 19991223 (60)
 US 1999-164059P 19991108 (60)
 US 1999-159362P 19991014 (60)
 DT Utility
 FS GRANTED
 INCL INCLM: 424/085.100
 INCL INCLM: 424/085.000; 514/002.000; 514/008.000; 514/012.000
 NCL NCLM: 424/085.100
 NCL NCLM: 514/002.000; 514/008.000; 514/012.000
 IC ICM: A61K038-19
 EXP 424/85.1; 424/885; 514/2; 514/8; 514/12
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L24 ANSWER 6 OF 13 USPTAFUL
 AN 2002:297455 USPTAFUL
 TI Methods and compositions for making dendritic cells from expanded
 IN populations of monocytes and for activating T cells
 PA Nelson, Edward L., Eldersburg, MD, United States
 PA Strodl, Susan L., Hagerstown, MD, United States
 PA The United States of America as represented by the Secretary of the
 Department of Health and Human Services, Washington, DC, United States
 (U.S. government)
 PI US 6479286 B1 20021112
 MO 9853048 19991126 20000605 (9)
 AI US 2000-424173 19990520 20000605 PCT 371 date
 PRAI US 1997-47348P 19970521 (60)
 DT Utility
 FS GRANTED
 INCL INCLM: 435/377.000
 INCL INCLM: 435/325.000; 435/375.000; 435/455.000; 424/093.100; 424/093.400;
 NCL NCLM: 435/377.000
 NCL NCLM: 424/093.100; 424/093.400; 424/093.710; 435/325.000; 435/375.000;

IC 435/455.000
 [7]
 ICM: C12N005-00
 ICS: C12N015-63; A61K035-00
 EXP 435/325; 435/375; 435/377; 435/455; 514/44; 424/93.21; 424/93.71
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L24 ANSWER 7 OF 13 USPTAFUL
 AN 2002:230597 USPTAFUL
 TI Non-myceloablative tolerogenic treatment
 IN Slavina, Shimon, Jerusalem, ISRAEL
 PA Prigozhina, Tatyana, Rehovot, ISRAEL
 PA Hadassah Medical Research Services and Development Ltd., Jerusalem, ISRAEL (non-U.S. corporation)
 PI US 6447767 B1 20020910
 AI US 2000-506082 20000216 (9)
 RLI Continuation-in-part of Ser. No. US 1998-222011, filed on 31 Dec 1998
 Continuation-in-part of Ser. No. US 1997-862550, filed on 23 May 1997,
 now abandoned
 DT Utility
 FS GRANTED
 INCL INCLM: 424/093.100
 INCL INCLM: 424/093.210; 514/002.000; 514/044.000; 435/325.000
 NCL NCLM: 424/093.100
 NCL NCLM: 424/093.210; 435/325.000; 514/002.000; 514/044.000
 IC ICM: A61K038-00
 ICS: A61K048-00; C12N015-85
 EXP 424/93.21; 424/93.1; 514/2; 514/44
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L24 ANSWER 8 OF 13 USPTAFUL
 AN 2001:170889 USPTAFUL
 TI Monocyte-derived dendritic cell subsets
 IN Punnonen, Juhna, Palo Alto, CA, United States
 PI Chang, Chia-Chun J., Los Gatos, CA, United States
 AI US 2001026937 A1 20011004
 AI US 2001-760388 A1 20010110 (9)
 PRAI US 2000-175552P 20000111 (60)
 US 2000-181957P 20000210 (60)
 DT Utility
 FS APPLICATION
 INCL INCLM: 435/366.000
 INCL INCLM: 435/325.000; 435/373.000; 424/093.210
 NCL NCLM: 435/366.000
 NCL NCLM: 435/325.000; 435/373.000; 424/093.210
 IC ICM: A61K048-00
 ICS: A01N063-00; C12N005-00; C12N005-02
 L24 ANSWER 9 OF 13 USPTAFUL
 AN 2001:119059 USPTAFUL
 TI Immunomodulating compositions for treatment of immune system
 IN disorders
 IN Kang, Romeo G., Bucharest, Romania
 PI Percheson, Paul B., Ontario, Canada
 AI US 2001009680 A1 20010726
 AI US 2001-764010 A1 20010117 (9)
 RLI Continuation of Ser. No. US 1995-404932, filed on 16 Mar 1995, ABANDONED
 DT Utility
 FS APPLICATION
 INCL INCLM: 424/528.000

NCL NCLM: 424/528.000
 IC [7]
 ICM: A61K035-413

L24 ANSWER 10 OF 13 USPTAFULL
 AN 2000:149714 USPTAFULL
 TI Allogeneic cell therapy for cancer following allogeneic stem cell
 IN transplantation
 PA Slavin, Shimon, Jerusalem, Israel
 PI Baxter International Inc., Deerfield, IL, United States (U.S.
 corporation)
 DT Hadassit Medical Research Services and Development Ltd., Jerusalem,
 FS Israel (non-U.S. corporation)
 LN CNT 20001107
 INCL US 6143292
 WO 9637208 19961128 19971121 (8)
 US 1997-890071 19960524
 WO 1996-US7652 19971121 PCT 371 date
 19971121 PCT 102(e) date

RLI Continuation-in-part of Ser. No. US 1995-449764, filed on 25 May 1995,
 now abandoned.

DT Utility
 FS Granted
 LN CNT 1347

INCL INCLM: 424/093.700
 INCLS: 424/093.710; 424/085.500; 424/085.700; 424/085.200; 424/085.400;
 424/144.100; 424/577.000; 424/578.000; 435/325.000; 435/375.000

NCL NCLM: 424/093.700
 NCLS: 424/085.200; 424/085.400; 424/085.500; 424/085.700; 424/093.710;
 424/144.100; 424/577.000; 424/578.000; 435/325.000; 435/375.000

IC [7]
 ICM: A61K035-28
 ICS: C12N005-08
 424/93.71; 424/93.7; 424/85.5; 424/85.7; 424/85.2; 424/85.4; 424/144.1;
 424/577; 424/578; 435/325; 435/372

EXF 424/577; 424/578; 435/325; 435/372

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 11 OF 13 USPTAFULL
 AN 97:44908 USPTAFULL
 TI WT1 monoclonal antibodies and methods of use therefor
 IN Herlyn, Meenhard, Wynwood, PA, United States
 Morris, Jennifer, Brookfield, WI, United States
 Rauscher, III, Frank J., Cranbury, NJ, United States
 PA Rodeck, Ulrich, Philadelphia, PA, United States
 The Wistar Institute of Anatomy and Biology, Philadelphia, PA, United
 States (U.S. corporation)
 PI US 5633142 19970527
 US 1995-456907 19950601 (8)
 Continuation-in-part of Ser. No. US 1994-234783, filed on 28 Apr 1994

DT Utility
 FS Granted
 LN CNT 1214

INCL INCLM: 435/007.230
 INCLS: 435/007.100; 435/007.200; 435/007.210; 530/387.100; 530/387.700;
 530/388.100; 530/388.800; 530/809.000

NCL NCLM: 435/007.230
 NCLS: 435/007.100; 435/007.200; 435/007.210; 530/387.100; 530/387.700;
 530/388.100; 530/388.800; 530/809.000

IC [6]
 ICM: G01N033-547
 ICS: G01N033-53; C07K016-30; C07K016-18
 435/7.23; 435/7.1; 435/7.2; 435/7.21; 530/387.1; 530/387.7; 530/388.1;
 530/388.8; 530/809

EXF 435/7.23; 435/7.1; 435/7.2; 435/7.21; 530/387.1; 530/387.7; 530/388.1;
 530/388.8; 530/809

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 12 OF 13 USPTAFULL
 AN 97:33630 USPTAFULL
 TI WT1 monoclonal antibodies
 IN Herlyn, Meenhard, Wynwood, PA, United States
 Morris, Jennifer, Wilmington, DE, United States
 Rauscher, III, Frank J., Cranbury, NJ, United States
 PA Rodeck, Ulrich, Philadelphia, PA, United States
 The Wistar Institute of Anatomy & Biology, Philadelphia, PA, United
 States (U.S. corporation)
 PI US 5622835 19970422
 US 1994-234783 19940428 (8)

DT Utility
 FS Granted
 LN CNT 1265

INCL INCLM: 435/328.000
 INCLS: 530/387.500; 530/387.900; 530/388.100; 530/388.800; 530/388.850;
 435/070.210; 435/172.200; 435/331.000; 435/344.000; 435/344.100

NCL NCLM: 435/328.000
 NCLS: 435/070.210; 435/331.000; 435/344.000; 435/344.100;
 530/387.300; 530/387.900; 530/388.100; 530/388.800; 530/388.850

IC [6]
 ICM: C12N005-12
 ICS: C07K016-00; C07K016-18; C07K016-30
 435/240.27; 435/172.2; 435/172.2; 435/70.21; 435/7.23; 530/387.3; 530/387.9;
 530/388.1; 530/388.85; 530/388.8

EXF 435/240.27; 435/172.2; 435/172.2; 435/70.21; 435/7.23; 530/387.3; 530/387.9;
 530/388.1; 530/388.85; 530/388.8

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 13 OF 13 USPTAFULL
 AN 90:57750 USPTAFULL
 TI Lateral flow, non-bidulous membrane assay protocols
 IN Eisinger, Robert W., San Diego, CA, United States
 Khalil, Mohammed H., San Diego, CA, United States
 Katz, David H., La Jolla, CA, United States
 PA Sargeant, Robert B., Ramona, CA, United States
 Onidel, San Diego, CA, United States (U.S. corporation)
 PI US 4943522 19900724
 US 1988-230642 19880810 (7)

DT Continuation-in-part of Ser. No. US 1987-57273, filed on 1 Jun 1987, now
 abandoned And a continuation-in-part of Ser. No. US 1987-57271, filed on
 1 Jun 1987, now abandoned

FS Utility
 Granted
 LN CNT 1768

INCL INCLM: 435/007.000
 INCLS: 435/805.000; 435/810.000; 436/512.000; 436/514.000; 436/518.000;
 436/520.000; 436/523.000; 436/531.000; 436/535.000; 436/807.000;
 436/808.000; 436/810.000; 422/055.000; 422/056.000; 422/057.000;
 422/058.000; 422/101.000

NCL NCLM: 435/007.250
 NCLS: 422/055.000; 422/056.000; 422/057.000; 422/058.000; 422/101.000;
 435/005.000; 435/007.210; 435/007.230; 435/007.320; 435/805.000;
 435/810.000; 436/512.000; 436/514.000; 436/518.000; 436/520.000;
 436/523.000; 436/531.000; 436/535.000; 436/807.000; 436/808.000;
 436/810.000; D24/223.000

IC [5]
 ICM: G01N033-53
 422/55-61; 422/70; 422/101; 422/102; 424/11; 435/7; 435/5; 435/805;
 435/810; 436/514-520; 436/512; 436/523; 436/531; 436/535; 436/807;
 436/808; 436/810; 210/431

EXF 422/55-61; 422/70; 422/101; 422/102; 424/11; 435/7; 435/5; 435/805;
 435/810; 436/514-520; 436/512; 436/523; 436/531; 436/535; 436/807;
 436/808; 436/810; 210/431

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

==>
 ---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	190.99	191.20

STN INTERNATIONAL LOGOFF AT 14:48:34 ON 12 FEB 2003

=> d 17 18 ibib ab

L16 ANSWER 17 OF 18 MEDLINE DUPLICATE 1
ACCESSION NUMBER: 91187141 MEDLINE
DOCUMENT NUMBER: 91187141 PubMed ID: 2011210
TITLE: Distribution of carbohydrate structures in individual maturation stages of myeloid leukemic cells.
AUTHOR: Noworolska A; Slesak B; Harlonzinska A; Richter R
CORPORATE SOURCE: Department of Pathological Anatomy, School of Medicine, Wroclaw, Poland.
SOURCE: NEOPLASMA, (1991) 38 (1) 57-62.
Journal code: 0377266. ISSN: 0028-2685.
PUB. COUNTRY: Czech Republic
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199105
ENTRY DATE: Entered STN: 19910526
Last Updated on STN: 19960719
Entered Medline: 19910503

AB The distribution of peanut agglutinin (PNA) receptors, nonspecific cross-reacting antigen (**NCA**) molecule and 3-fucosyl-N-acetyllactosamine (FAL) in myeloid leukemic cells isolated by density gradient centrifugation was compared using immunofluorescence test (IF). Patients with acute myelocytic leukemias (AML) type M2 and M5 showed low percentage of **NCA**+ and PNA+ cells. In chronic and acute phase of chronic myelocytic leukemias (**CML**) the number of **NCA** containing cells increased and the amount of PNA-binding cells decreased as more mature granulocytic fractions were isolated on Ficoll-Uroline density gradient. In patients with myeloblastic crisis of **CML** (**CML-BC**) the number of cells expressing FAL structure did not change in relation to maturation stage of myeloid cells. Our results revealed that the expression of various markers could change in a different way during the differentiation of cells from myeloblasts to mature **granulocytes**.

L16 ANSWER 18 OF 18 MEDLINE DUPLICATE 2
ACCESSION NUMBER: 82141196 MEDLINE
DOCUMENT NUMBER: 82141196 PubMed ID: 6949877
TITLE: Clinical evaluation of **NCA** in patients with chronic myelocytic leukemia.
AUTHOR: Wahren B; Gahrton G; Ruden U; Hammarstrom S
SOURCE: INTERNATIONAL JOURNAL OF CANCER, (1982 Feb 15) 29 (2) 133-7.
Journal code: 0042124. ISSN: 0020-7136.
PUB. COUNTRY: Denmark
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198205
ENTRY DATE: Entered STN: 19900317
Last Updated on STN: 19900317
Entered Medline: 19820512

AB **NCA**, a normal colon and **granulocyte** antigen, which has been found in large amounts in myelocytes and metamyelocytes and in smaller amounts in neutrophil **granulocytes**, was studied in 50 **CML** patients in various stages of the disease. Radioimmunoassay was used to demonstrate **NCA** in serum. Untreated **CML** patients had a mean level of 732 micrograms **NCA**/l, poorly controlled patients 421 micrograms/l and well-controlled patients 160 mu/l. These values differ significantly from the mean of healthy persons, which was 71 micrograms **NCA**/l. The serum **NCA** levels were related to the number of maturing myeloid cells in blood, and to the clinical course in the chronic phase of **CML**. In blast crisis low

values with a mean of 109 micrograms **NCA**/l was found. Patients with ANLL had a low mean level, 50 micrograms/l. Low levels of **NCA** could not be attributed to **antibodies** to **NCA**.

NCA is a normal myeloid differentiation antigen. Despite this, its occurrence in serum in leukemic patients differs from normal. This probably has to do with the abnormal amount as well as the release of **NCA** by leukemic maturing myeloid cells.

L21 ANSWER 1 OF 1 MEDLINE
 AN 92293167 MEDLINE
 DN 92293167 PubMed ID: 1603094
 TI Microheterogeneity of a purified IgG1 due to asymmetric Fab glycosylation.
 AU Grebenau R C; Goldenberg D M; Chang C H; Koch G A; Gold D V; Kunz A;
Hansen H J
 CS Immunomedics Inc., Newark, NJ 07103.
 NC CA 39841 (NCI)
 SO MOLECULAR IMMUNOLOGY, (1992 Jun) 29 (6) 751-8.
 Journal code: 7905289. ISSN: 0161-5890.
 CY ENGLAND: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199207
 ED Entered STN: 19920724
 Last Updated on STN: 19920724
 Entered Medline: 19920713

=> d 121 ab

L21 ANSWER 1 OF 1 MEDLINE
 AB A murine monoclonal anti-granulocyte IgG1, IMMU-**MN3**, was seen to exhibit heterogeneity. On reduced SDS-PAGE, the purified antibody appeared as two heavy-chain bands of unequal intensity, and only one light-chain band. Hydrophobic interaction chromatography (HIC) also resolved two populations of the IMMU-**MN3** antibody. Based on Concanavalin A affinity chromatography, enzymatic digestion with Endoglycosidase F and carbohydrate analysis, it was found that the heterogeneity detected by SDS-PAGE and HIC was due to differences in glycosylation. Furthermore, sequential gel analysis (non-reduced/reduced) demonstrated that the upper heavy-chain band was asymmetrically glycosylated.

ACCESSION NUMBER: 89000602 EMBASE

DOCUMENT NUMBER: 1989000602

TITLE: In vivo labelling of granulocytes using 123I-tagged anti-granulocyte antibodies.

AUTHOR: Seybold K.

CORPORATE SOURCE: Department of Nuclear Medicine, Kantonsspital, CH-5001 Aarau, Switzerland

SOURCE: Nuclear Medicine Communications, (1988) 9/10 (745-752).

ISSN: 0143-3636 CODEN: NMCODC

COUNTRY: United Kingdom

DOCUMENT TYPE: Journal

FILE SEGMENT: 008 Neurology and Neurosurgery
015 Chest Diseases, Thoracic Surgery and Tuberculosis
023 Nuclear Medicine
025 Hematology
026 Immunology, Serology and Transplantation
033 Orthopedic Surgery
037 Drug Literature Index

LANGUAGE: English

SUMMARY LANGUAGE: English

AB On the basis of previous work with various monoclonal antibodies (Mab) raised against carcinoembryonic antigen (CEA), the anti-CEA Mab 47 was identified which selectively reacted with a surface glycoprotein (95 kDa; NCA 95) of normal human granulocytes. This new tracer was quality tested and radioiodinated with 123I (123I Mab 47) for clinical use according to established procedures. Extended in vitro studies revealed a high selectivity for granulocytes without inhibiting their vital functions. In vivo cell binding to the granulocyte pool was completed very rapidly and remained unchanged over 24 h. For clinical use one dose consisting of 120 mcg of Mab was labelled with 4-5 mCi of 123I. Clinical interest was mainly concentrated on cases of osteomyelitis, infected allografts and abdominal and brain abscesses. After injection of 123I Mab 47, infectious lesions were usually seen after 3-5 h or could be excluded after 24 h. Because of high counting rates the image quality was excellent and single photon emission computerized tomography (SPECT) could be performed for an exact topographical localization of the lesions. No adverse reactions have been seen. It is concluded that there are distinct advantages of the new method compared with scanning of 111In-labelled leucocytes. However, despite this and the low dose of antibodies administered, we recommend restriction of immunoscintigraphy of infectious lesions before a clinically relevant immunization can be excluded.